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Abstract 
Cancer is one of the leading causes of death in the world. In developing countries cancer is claiming more 
lives than HIV & AIDS, tuberculosis and malaria combined. Cancer is generally known to be a disease 
with uncontrolled multiplication; in other words, cells reproduce in defiance of normal restraints on cell 
division. It is also known to invade and colonize territories far from the infection area. 
As the science of cancer is developing, researchers are seeing light at the end of the tunnel. Cancer is 
known to be a disease of genetic disorders, though it is much more than that with hallmarks like evading 
apoptosis. Most of the chemotherapeutic drugs activate apoptosis by using p53 pathway. Unfortunately, 
in most of the cancer cases p53 is mutated; therefore efforts were made to bypass this mutation since it 
happens upstream and make molecules that target further downstream in the signal pathway. 
It is the aim of this thesis to shed more light on the possibility of targeting not only downstream targets in 
the apoptosis cascade, but the main executioner which is caspase-3. The idea was to make more potent 
derivatives of PAC-1, which can lead to cell death and hopefully new leads for cancer drugs. A total of 
five compounds were synthesized including PAC-1 as a positive control. The compounds were 
characterised with the help of 
1
H NMR, 
13
C NMR and LC-MS. They were later subjected to biological 
testing whereby PC-12 cells were treated with the compounds. After 48 hours of incubation the cell 
viability was measured.  It was found that all the compounds had an effect in reducing cell viability. 
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ABC    ATP-binding cassette 
Apaf-1    Apoptotic protease activating factor 
ATM-PK   Ataxia telangiectasia mutated protein 
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BIR    Baculovirus IAP repeat 
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CDK    Cyclin dependent kinase 
DD    Death domain 
DED    Death effector domain 
DISC    Death inducing signalling complex    
DNA-PK   DNA-dependent protein kinase 
dNTPs    Deoxyribonucleside triphosphate 
DTMP    Deoxythymidylate 
ECM    Extra cellular matrix 
FADD    Fas associated death domain 
FDUMP   Fraudulent nucleoside fluorodeoxyuridine    
HTS    High throughput screen    
IAP    Inhibitors of apoptosis 
IGF     Insulin growth factor    
Mab    Monoclonal antibodies 
NTP    Nucleoside triphosphate 
PAC-1    Procaspase activating molecule 
PARP-1   Poly-ADP-ribose polymerase 
PETCM   α-trichloro methyl-4-pyridin-ethanol 
PHAP    Putative HLA-DR associated protein 
ProT    Prothymosin- α 
pRB    Retinoblastoma proteins 
RIP    Receptor interacting protein 
SAR    Structural activity relationship 
TGF    Transdermal growth factor 
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1.   Introduction                                                                                                                                             
Research on apoptosis has had tremendous increase and interest in the last two decades. With 
hundreds of thousands articles in the literature, one can experience the pace at which this field 
is moving. The reason why there is a great deal of interest in this field is simple, excess of 
apoptosis leads to the following diseases: myocardial infarction, stroke, sepsis, Alzheimers, 
Parkinson, Huntington disease and rheumatoid arthritis, while a decrease in apoptosis is 
associated with cancer and viral infection.  
 
The discovery and development of new drugs often involves lead compounds. These are 
compounds with not only interesting biological activities but also other characteristics like 
high toxicity and absorption difficulties. Procaspase activating compound (PAC-1) was a 
compound discovered through high throughput screening (HTS) by Hergenrother et al. in late 
2006. This compound was reported to be the first to directly cleave procaspase-3 to caspase-3, 
thereby inducing cell death.  
 
1.1 The aim of the project 
 To synthesize a series of analogues with variation on the phenol moiety 
 To conduct SAR studies on the compounds  
 To test the compounds for biological activity 
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1.2. Cancer 
Cancer is one of the leading causes of death in the world. In 2007, there were an estimated 12 million new 
cases of cancer and 7.6 million people died of cancer globally. By 2050, the global cancer burden is 
expected to grow to 27 million new cases and 17.5 million deaths every year. The trend is increasing at an 
alarming rate in developing countries. Cancer is killing more people in the developing world than HIV & 
AIDS, malaria and tuberculosis combined
1
.  
 
The development of cancer is complex and dependent on many factors. Some of these factors are more 
important than others, for example genetic constitution of an individual and the environment around the 
person. Regardless of circumstances, mutation is unavoidable, because it is an inescapable consequence 
of fundamental limitations on the accuracy of DNA replication. On the other hand environmental factors 
that play a part in the disease causation can be avoidable or at least postponable
2
. Considering this one 
third of the cancer in developing countries is preventable, and another one third more is detectable and 
treatable while there is still hope for survival
1
. 
 
Cancer is a disease in which there is uncontrolled multiplication of cells, in other words cells reproduce in 
defiance of the normal restraints on cell division. Another property which is shown by these cells is 
invading and colonizing territories far from infection area which are reserved for normal cells
2 and 3
. The 
term cancer, malignant neoplasm and malignant tumours are synonymous; they are distinguished from 
benign tumors by following properties: dedifferentiation, invasion and metastasis (the ability to spread to 
other parts of the body via blood or lymph). What both benign and malignant tumors share is the 
characteristic of uncontrolled proliferation
3
. 
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1.3. Pathophysiology of cancer 
Even if cancer is a disease with great diversity, efforts were made to characterise its pathophysiology so 
that a number of properties can characterise cancer cell. For a cell to be successful in its cancer 
acquisition it has to have a whole range of aberrant properties, the following six key properties make 
cancer cells capable of growth
2
.  
1. Self sufficiency in growth signals 
2. Insensitivity to antigrowth signals  
3. Evading apoptosis 
4. Limitless replicative  potential 
5. Sustained angiogenesis 
6. Tissue invasion and metastasis 
 
1.3.1. Self sufficiency in growth signals 
Normal cells require mitogenic growth signals before they move from a quiescent state into an active 
proliferative state
4 and 5
. These signals are generally external factors like diffusible growth factors, 
extracellular matrix components and cell to cell adhesion molecules
5
. Cancer cells generate their own 
growth signals in an autocrine fashion or by over expressing growth signal receptors to become hyper-
responsive to normal tissue levels of growth factors. This leads to reduction of their dependency on 
stimulation from their normal tissue microenvironment
4 and 6
. The cancer cells can do this by any of the 
following: alteration of extracellular growth signals, alteration of transcellular transducers of the signals, 
or alteration of intracellular circuits that translate those signals into action
4
. 
 Before a cell can replicate or divide several other things have to be taken care of including doubling of 
cell mass and chromosome segregation
5
. The coordination of cell cycle event is ordered in S, G2, M and 
G1 phases, where S and M phases represent replication and mitosis respectively, while the G phases 
represent the gaps or time delays to allow the cell growth
2 and 5
. See figure 1 in page 11 for description. 
During the gap phases, the system determines whether the cell cycle either proceeds or comes to halt 
momentarily or permanently due to DNA damage. These gaps or checkpoints allow time for repair 
enzymes to correct the lesion. In cancer cells regulatory proteins at the checkpoints are inactivated
5
. 
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Figure 1. The cell cycle corresponds to the four different phases, each having a distinct function. In G1 
phase the cells are prepared to divide, in the S phase cell division/replication takes place. In G2 phase 
chromosomes are doubled and mitosis initiated, whereas in M phase the actual chromosome separation 
and cell division takes place. This cycle is under strict regulation with RB, CDKs and cyclins being the 
major players 
9
.   
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1.3.2. Insensitivity to antigrowth signals   
Normal cells have antiproliferative signals that maintain tissue homeostasis. These signals are found both 
as soluble growth inhibitors and immobilized ones in the extracellular matrix. Antigrowth signals work 
by two ways; either forcing cells out of proliferation into a quiescent state (GO) from which the cell can 
re-emerge later when the cell cycle sees it fit, or the cell might be induced to enter post mitotic state. 
Cancer cells have to find a way of evading both possibilities
4 and 5
. Most antiproliferative signals use 
retinoblastoma proteins (pRB) and it is relatives like p107 and p13
4 and 6
.  
The following molecular process takes place before a cell is either sent to a quiescent or a post mitotic 
state is the following. When DNA is damaged, both ataxia-telangiectasia mutated protein kinase (ATM-
PK) and DNA dependent protein kinase (DNA-PK) are activated. They will in turn activate the tumour 
suppressor p53; this will in turn activate p21, which mediates cell cycle arrest through dephosphorylation 
of the retinoblastoma protein (pRB)
7
. When in a hypophosphorylated state, pRB blocks proliferation by 
alterating the function of E2F transcription factors that control the expression of genes necessary for the 
progression from G1 into S phase
4
. In cancer cells, pRB is disrupted resulting in liberation of E2F, which 
allows cells to proliferate, rendering them insensitive to antigrowth factors that normally operate along 
the way
 4
.   
Another molecule that is controlled by pRB is the oncogenic Id. See figure 2 in page 13 for the 
mechanism. The suppression of this molecule is concentration dependent; meaning when the Id 
concentration overrides the pRB amount controlling it, tumour cells proliferate
8
. Signalling molecules 
like TGFβ, for example prevent the phosphorylation that inactivates pRB, meaning TGFβ blocks the 
advance through G1
4 and 5
. The pRB circuit governed by the TGFβ can be disrupted in several ways by the 
cancer cells; TGFβ can lose responsiveness through down regulation of TGFβ receptors on the cancer 
cells, while others can display mutant or dysfunctional receptors
4
.  
 The other way of taking care of DNA damage was to instruct cells to irreversibly enter post mitotic, 
differentiated states. It is therefore apparent that tumour cells must use various strategies to avoid this 
terminal differentiation. One such strategy is c-Myc over expression, which leads to Myc-Max complexes 
that favours growth instead of normal expression of c-Myc, which forms Mad-Max complexes that 
favours terminal differentiation
4.
 
 
 13 
 
 
 
Figure 2. The Myc proteins are targets for both mitogenic and antimitogenic signals. When activated by 
mitogenic signals, they become powerful oncoproteins.  They bind to the E boxes of the Id 2 promoter and 
activate transcription. The Id 2 increases in concentration so that the pRB, which inhibits it, is defeated. 
The Id 2 will then be free to inhibit the natural targets that control cell proliferation 
8
.  
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1.3.3. Evading apoptosis 
In order to achieve uninterrupted proliferation, cancer cells must not only divide continuously they must 
also find a way of evading apoptosis, since expansion of tumor cell is determined not only by the rate of 
cell proliferation but also by the rate of cell attrition
4
.
 
The apoptotic program is present in virtually all 
cells in a latent form. Once triggered this program unfolds into a controlled series leading to disruption of 
cellular membranes, breakdown of the cytoplasmic and nuclear skeletons, extrusion of cytosol, 
degradation of chromosomes and fragmentation of the nucleus. In the end, the waste of such a process is 
engulfed by nearby cells in a tissue and disappears
4
. 
Avoiding or resisting apoptosis is a complex process, which manifest in either of two ways. The first way 
is through changes in susceptibility to death signals. This effect is mediated by changes in the cells 
apoptotic machinery represented by proteins from the Bcl-2 family, the p53 tumor suppressor protein, or 
the CD95 receptor CD95/ligand system. The second way manifests itself as changes in the cells survival 
system represented by insulin-growth factor IGF/IGFR pair
10
. 
 Resistance to apoptosis occurs when the genes facilitating apoptosis are impaired; an example of such a 
gene is p53
4
. This gene is involved in cell cycle control, apoptosis and even maintenance of genetic 
stability. Cells defective of p53 can therefore escape apoptosis and continue dividing when their DNA is 
damaged. A consequence of defective p53 is that chromosomes get fragmented and incorrectly rejoined 
creating further rounds of cell division. Such chromosomal mayhem can lead to both loss of tumor 
suppressor genes and activation of oncogenes
2
. 
Apoptosis is an extremely important process; therefore, the final effectors of apoptosis are tightly 
regulated. The inhibitors of apoptosis protein (IAP) are the only endogenous proteins that regulate 
initiator and effector caspases
11 and 12
. Figure 3 in page 15 describes the structural difference between the 
inhibitors of apoptosis proteins. The human IAPs are seven in number, currently only X-linked inhibitor 
of apoptosis protein (XIAP) is the suggested to both bind caspases and inhibit apoptosis. The others like 
cIAP1 and cIAP2 binds caspases but are not direct antagonist
11
. 
 
 
 
 
 
 15 
 
 
 
Figure 3. Domain structure of human inhibitors of apoptosis proteins. The presence of at least one 
baculovirus IAP repeat (BIR) is a defining characteristic of the IAP protein
11
. 
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1.3.4. Limitless replicative potential     
The three properties named above constitute all cell to cell signalling. Having defects in only cell-to-cell 
signalling alone does not lead to growth of cancerous tumours. Each cell has its own intrinsic, cell 
autonomous program that limits their multiplication. Cells have finite replicative potential. Once the cell 
population has progressed through a certain amount of doubling, they stop growing. This process is called 
senescence
4
.  
This senescence can be circumvented by disabling pRB and p53 tumour suppressor gene, which leads to 
continued multiplication of the cell until it reaches a state termed crisis. This crisis state is characterised 
by massive cell death, karyotypic disarray associated with end-to-end fusion of chromosomes and the 
emergence of 1 in 10
7
which has acquired the ability to multiply without cell death
4
. 
This limitless replication is seen when a cell starts losing its telomeric DNA. See the figure below for 
illustration. When telomeres are lost the ability to protect the ends of chromosomal DNA is also lost. The 
unprotected chromosomal end participates in end to end chromosomal fusion leading to the karyotypic 
disarray associated with the early crisis
4 and 13
.  
This early crisis can be circumvented by the Hayflick limit, but an inactivation of these limits can give 
advance to early crisis. Continuation of this crisis from an early stage to late stage is hindered by active 
p53. If the late crisis is reached and no telomere maintenance is evident the cell survives
13
. Telomere 
dysfunction is evident in all types of cancer. This is possible by either upregulating the expression of 
telomerase enzyme or by activating ALT, which appears to maintain telomeres through recombination 
based interchromosomal exchanges of sequence information
4
. 
 
Figure 4. With cell division in the absence of telomerase, the telomere erodes. Such erosion of telomere 
elicits Hayflick limit preventing the cell from entering an early crisis. Inactivation of Hayflick limit leads 
to early crisis, which can proceed to late crisis if not averted by active p53. When p53 is bypassed and no 
telomere maintenance is evident, cell survival is a factum 
13
. 
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1.3.5. Sustained angiogenesis 
Mammalian cells are to be located within 100-200µm of blood vessels which is the diffusion limit if they 
are to be supplied with oxygen and other nutrient necessary for survival. Growth beyond that distance 
requires recruitment of new blood vessels by vasculogenesis and angiogenesis
14 and 15
. For an illustration 
of how blood vessels are formed, see figure 5 in page 18. 
Without blood vessels, tumours can neither grow beyond critical size nor metastasize to other organs. In 
addition, without efficient blood supply delivery of anti cancer drugs to all tumour regions in effective 
quantities would not be possible
14
. 
There is a balance between the positive and negative signals, which encourage or block angiogenesis 
respectively and such a balance is termed as the angiogenic switch
4, 14 and 15
. The angiogenic switch is off 
when the effect of pro-angiogenic molecules is balanced by that of anti-angiogenic molecules and on 
when the balance is tipped in favour of angiogenesis
14, 15 and 16
.  Various signals can trigger this switch, 
including metabolic stress, mechanical stress, immune/ inflammatory response and genetic mutations
14
.  
One class of the signal conveyers that initiate angiogenesis is vascular endothelial growth factor (VEGF)
 
14
. Integrins and adhesion molecules mediating cell to matrix or cell to cell association play critical roles 
also. A class of angiogenesis inhibitors is thrombospondin-1. Integrins contribute to this regulation, 
whereby quiescent vessels express one class of Integrins while sprouting vessels express another; the 
signal interference with the latter can lead to inhibiting angiogenesis
4
. 
One usually finds a balance between the inducers and inhibitors. This balance can be tipped to favor 
vascularisation in two ways: either by increasing the concentration of the inducers or decreasing the 
concentration of the inhibitors
16
. One way of increasing inducer concentration is by altering the genetic 
transcription; this is evidenced by the increased expression of VEGF on tumour cells compared to their 
normal counterparts. The other way involves downregulation of endogenous angiogenesis inhibitors like 
thrombospondin
4
.  
Oncogenes can influence angiogenesis in the following ways. They can encode secreted proteins that are 
potent angiogenic factors; others can stimulate the production of angiogenic factors, while sometimes 
activated oncogenes can indirectly contribute to angiogenesis by stimulating the production and activation 
of a variety of enzymes that can degrade the matrix and basement membrane which sprouting vessels 
must transverse
16
.  
 18 
 
 
 
Figure 5.  Mechanisms of tumour angiogenesis. There are three different mechanisms: the first being 
vascular network expanding by budding of endothelial sprouts, this is termed as angiogenic sprouting. 
Secondly the tumour vessel can remodel and expand by insertion of interstitial tissue columns into the 
lumen of pre-existing vessels, this is called intussusceptions. Lastly endothelial cell precursors from the 
bone marrow flow into the tumour and contribute to the endothelial lining of tumour vessels 
(vasculogenesis) 
14
.  
 19 
 
 
 
 
Figure 6.  A circuit of the cell with all the involved mediators. Genes known to be functionally altered in 
cancer are highlighted in red 
4
.  
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1.3.6. Tissue invasion and metastasis   
With time most of human cancer cells develop pioneer cells that move out, invade adjacent tissues and 
travel to sites far from their origin, where they colonise and temporarily get unlimited nutrients and space 
4
. The migration to distant sites through the lymphatic system or bloodstream is what makes cancer 
deadly, as 90 % of cancer death is as a result of metastasis 
4, 17 and 18
.  
How successful invasion and metastasis are depends on the other hallmarks of cancer, but what makes 
them different from the other hallmarks? The answer to this question is that this two properties are 
complex processes whose genetic and biochemical determinants are not fully understood
4
. What is of no 
surprise; however is the mechanisms that propel invasive growth and metastasis are also found in 
embryonic development though to a less aggressive extent in tissue maintenance and repair processes
18
. 
 Cancer cells can preferentially bind to different types of cells like epithelial, fibroblast or even 
endothelial cells. What makes this possible for cancer cells are cell to cell adhesion molecules (CAM), 
and they fall into three main families, immunoglobulin, cadherins and the integrins 
4 and 18
. The best way 
to explain CAM involvement is E cathedrin .The function of E cathedrin is lost in the majority of 
epithelial cancer, the mechanism being inactivation of E cathedrin
4
.  
Forced expression of E cathedrin in cultured cancer cells impairs both invasion and metastasis, while 
interfering with E cathedrin enhances both capabilities
4
. This leads to the conclusion that CAMs are not 
simply superglues organizing cells in static structures, but support and direct the dynamic interchange of 
information between the two cells by interaction of the cytoplasmatic region and kinases as well as 
through other growth factor receptors
18
.  
The integrins also take part of invasion and metastasis.  They are essential for progression because when 
cancer cells invade and move away from the primary site they encounter a different environment that 
requires adaptation. Part of this adaptation can come from changing some of the integrins that favour 
extracellular matrix (ECM) to others that preferentially bind the degraded stromal components produced 
by extracellular proteases
4 and 18
. In addition they regulate signalling pathway which controls actin and cell 
movement
18
. 
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1.4. Current cancer management 
Anticancer drugs are divided into groups according to their mechanism. The groups are cytotoxic drugs, 
hormones, immune modulating drugs, cytokines and drugs against growth regulating factors. For a few 
groups, cancer drugs can lead to curing the disease, but for most types of cancer drug treatment is given 
only for palliative effect
22
. 
 
1.4.1. Cytotoxic drugs  
As the name implies these are drugs that lead to cell death. Some interfere with DNA synthesis, others 
with the RNA, others with the proteins and others with enzymes and microtubules. They are ordered into 
groups depending on their mechanism
3
.  
 
1.4.2. Alkylating agents  
They are defined as compounds capable of replacing a hydrogen atom in another molecule with an alkyl 
radical
19
.  Very many different compounds can function as alkylating agents, but only a few of these 
compounds are useful clinically
19
. Structure of the most commonly used alkylating drugs is shown below 
in figure 7.  
They have an alkyl group that forms a covalent bond with the cell substituent, meaning unlike other drugs 
in medicine their effect is as a result of covalent binding with cell constituents
3 and 19
. They form a 
carbonium ion i.e. a carbon atom with only six electrons in the outer shell; such atoms are highly reactive 
and react instantly with electron donors like amine, hydroxyl or sulfhydryls. Most of the alkylating agents 
have two such alkylating groups leading to a cross linking that results in defective replication because of 
the substitution of AT for GC, or it can cause excision of guanine and chain breakage
3
.
 
                                   
 
Figure 7. Alkylating agents belonging to nitrogen mustard analogue.  
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1.4.3. Antimetabolites  
Antimetabolites a class of anticancer drugs with resemblance to naturally occurring biological molecules 
and interfere with essential biochemical processes requiring native metabolites
20
. They can be divided 
into folate antagonists, pyrimidine and purine analogues. Methotrexate is an example of folate antagonist; 
it works by inhibiting dihydrofolate reductase, preventing the generation of tetrahydrofolate from folic 
acid resulting in interference with thymidylate synthesis and thus synthesis of DNA
3
. See figure 8 in page 
23 for structures. 
 Both antipurines and antipyramidines resemble 2
’
-deoxyadenosine (dA), 2
’
-deoxyguanosine (dG), 2
’
-
deoxycytosine (dC) and 2
’
- deoxythymidine (dT) respectively. They therefore interfere with the precursor 
pools required for DNA synthesis
20
. The nucleoside triphosphate (NTP) formed with the antipurines and 
antipyramidines gets incorporated into the DNA in place of the native dNTPs.  Such incorporation alters 
the structural and biochemical properties of DNA
20
. These altered properties are responsible for DNA- 
protein interaction that leads to the interference of the DNA repair and replication
20. 
Pyrimidine analogues interfere with 2 deoxythymidylate (DTMP), it’s converted to fraudulent nucleotide 
fluorodeoxyuridine (FDUMP), this cannot be converted to DTMP, resulting in the inhibition of DNA 
synthesis, but not RNA or protein synthesis
3
. Purine analogues are potent inhibitors of DNA synthesis 
owing to their direct inhibitory effect on ribonucleotide reductase
21
. 
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Figure 8. A summary of the most common anitimetabolites are presented in the figure. The first two 3 and 
4 represent folate antagonist, while the last two represents 5 and 6 are purine and pyrimidine analogues 
respectively. 
 
1.4.4. Cytotoxic antibiotics  
Cytotoxic antibiotics have their main effect by direct interference of DNA function. The main group is the 
anthracycline derivates like doxorubicin, epirubicin and daunorubicin. Other antibiotics with cytotoxic 
activity include mitomycin and streptozocin
3 and 22
. Mechanisms of action for the anthracycline derivates 
include: intercalating DNA, inhibiting topoisomerase II and generating free radicals. The other group of 
cytotoxic antibiotics are heterogeneous when it comes to both the mechanism and clinical use
22
. In page 
24 structures of some anthracyclines derivates are presented. 
The anthracyclines are the most clinically used cytotoxic antibiotics and the most effective anticancer 
drugs ever developed
23
. However, antibiotic resistance is a major problem with this class of drugs. One of 
the main reason for resistance is the over expression of membrane-located efflux pumps of the ATP-
 24 
 
binding cassette family (ABC transporters) 
24
. These are proteins that facilitate transport of the drug out of 
the cells before reaching their intracellular targets
24
.    
                                   
7                                                                  8 
Figure 9. Examples of some cytotoxic antibiotic; doxorubicin and daunorubicin as 7 and 8 are both 
anthracycline derivates. 
 
1.4.5. Natural products 
 The plant derivates are divided into the following groups: vinka alkaloids, taxanes, etoposide and 
camptothecins. The vinka alkaloids are vincristine, vinblastine, vinorelbine and vindisine. These are drugs 
that act by binding to tubulin and inhibit formation of protofilaments and microtubules, which prevents 
spindle formation in mitosing cells and cause arrest at metaphase
3, 22 and 25
. The structures of a few 
examples of plant derivatives are shown in figure 10 in page 25. 
The taxanes have different mechanisms of action than the vinca alkaloids which bind to tubulin, they 
instead bind to microtubules, stabilising them into polymerised state and interfering with the equilibrium 
between tubulin and microtubules
3, 22 and 25
. They also bind and inactivate microtubule thereby inhibiting 
mitosis
3 and 22
.  
Etoposide is derived from mandrake root, its mode of action is not clearly known, but it’s believed to act 
by inhibiting mitochondrial function
3 and 22
. Etoposide has no affinity for tubulin and doesn’t therefore 
have any effect on the microtubule assembly at clinically relevant levels. Its effect on toposiomerase II is 
thought to cause an irreversible premitotic block into the late S phase and early G2 phase
25
. The 
camptothecins inhibit topoisomerase I
3 and 22
. Camptothecins binds to a complex formed by DNA with 
topoisomerase I, thereby inhibiting protein synthesis and cell division
25
. 
 
 25 
 
9 10 
                                                                            
                                                                    
11            
Figure 10. Some natural products used in cancer therapy, 9 is vinblastine, 10 is vinolrelbin and 11 is 
paclitaxel                 
                                              
1.4.6. Hormones  
Some tumours can be hormone dependent, use of hormone antagonist or substances that inhibit the 
synthesis of relevant hormones can be useful drugs for such tumours. As of today the following are 
hormones that are used as cancer drugs: glucocorticoids for leukaemias, tamoxifen for breast cancer, anti- 
androgen for prostate cancer and inhibitors of sex hormones synthesis for postmenopausal breast cancer
3
. 
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1.4.7. Monoclonal antibodies  
Monoclonal antibodies are a new class of drugs; they are also called target therapies.  One can distinguish 
between targeted and none- targeted therapies, the former referring to monoclonal antibodies and the 
latter to traditional chemotherapy
26
.
  
Targeted therapies are designed to selectively inhibit a target that is abnormal and malignant compared to 
normal cells
26
. Targeted therapies work on proximal events in signal transduction cascade rather than 
affecting the downstream outputs of these pathways
26
. See figure 11 below. This results in drugs with 
fewer side effects but they are also susceptible to downstream resistance. 
They are immunoglobulins that react with a specific molecular target. They can be part mouse, part 
human or fully human. The following are in the Norwegian market per today with cancer as an indication: 
alemtuzumab, bevacizumab, Cetuximab, rituximab and trastuzumab
3 and 22
 
 
 
Figure 11. Subcellular localization of targeted and none - targeted therapies. Targeted here means 
biological or monoclonal antibodies, while none - targeted refers to traditional chemotherapy. Target A 
refers to targeted therapy; with b and c being pathways which can result in resistance for target A. 
Target B is less susceptible to this resistance. Target C and D represent none - targeted therapies and are 
less affected by upstream event 
26
.  
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1.5. Cell death 
Naturally occurring cell death plays a critical role in many normal processes like foetal development and 
tissue homeostasis
31
. Cell death can be differentiated according to its morphological appearance like 
apoptosis, necrosis, autophagical etc, according to enzymological criteria like involvement of nucleases, 
proteases, caspases, calpains, or because of functional aspects (programmed or accidental, pathological or 
physiological) or because of immunological characteristics like (immunological or non immunological) 
27
.  
Cell death is usually discussed as apoptosis and necrosis, where the former means programmed and the 
latter accidental. Since it is programmed apoptosis avoids eliciting inflammation. Necrosis, on the other 
hand is passive and accidental which results from environmental disturbances leading to uncontrolled 
release of inflammatory cellular contents
28
. Recently, research has proved that necrosis appears to be a 
well regulated event carried out by a set of controlled signal transduction pathways and execution 
mechanisms that contribute to both the development and maintenance of homeostasis
29 and 30
.  
Accordingly the nomenclature committee on cell death has proposed in October 2008 unified criteria for 
the definition of cell death according to its morphology. Apoptosis is thus not defined as programmed cell 
death but occurs only when the following morphological aspects of cell death are seen: reduction of 
cellular volume, chromatin condensation, nuclear fragmentation, little or no ultra structural modification 
of cytoplasmic organelles, plasma membrane blebbing and engulfment by phagocytes.  
Autophagic cell death is defined as cell death that occurs in the absence of chromatin condensation, but 
accompanied by massive autophagic vacuolization of the cytoplasm. Necrotic cell death is characterised 
by gain in cell volume (oncosis), swelling of organelles, plasma membrane rupture and loss of 
intracellular contents
27
. The different type of cell deaths and their end results are shown in figure 12 on 
page 28. 
Cell death whether it comes by apoptosis or necrosis has both physiological and pathological effects.  
With suppression of cell death one encounters diseases like cancer, atherosclerosis and autoimmune 
disorders, while increased cell death has a direct link with viral infections like AIDS; neurodegenerative 
disorders like Alzheimer’s disease; autoimmune disorders like multiple sclerosis; haematological 
disorders like myelodysplastic syndromes and ischemic injuries like myocardial infarction etc
30 and 31
. 
 28 
 
 
 
Figure 12. A summary of the type of cell death a normal cell can undergo depending on the type of 
stimuli with it is characteristic features, while the three major types like apoptosis, necrosis and 
autophagy are known, pyroptosis is mediated by caspase-1 which activates inflammation 
28. 
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1.5.1. Necrosis 
Until 1971 all types of cell death were termed necrosis. In 1971 Kerr et.al observed the first none- 
pathological cell death and termed it shrinkage necrosis. They later renamed it apoptosis when they saw 
that it was implicated in the organ`s homeostasis
30
. Necrosis was, until October 2008, defined as the 
opposite of apoptosis, or in other words cell death not mediated by apoptosis was termed as necrosis
30 
Necrotic cell death or necrosis as it is shortly termed is defined as having the following morphological 
characteristics: gain in cell volume (oncosis), swelling of organelles, plasma membrane rupture and 
subsequent loss of intracellular contents
27
. Despite the wide spread belief that necrosis is uncontrolled, 
accidental, or default cell death, accumulating studies have evidenced that the execution of necrotic cell 
death may be regulated by a set of well defined signal transduction pathways
27, 29 and 30
. 
It was recently shown that triggering of Fas or tumor necrosis factor that is usually the cornerstone of the 
apoptosis pathway, can induce necrotic cell death in the presence of caspase inhibitors or absence of Fas-
associated death domain (FADD)
29
. Necrostatins are the first class of inhibitors of in vitro necrotic cells; 
these necrostatins inhibit receptor interacting protein 1 (RIP) 1 kinase activity. Owing to the lack of 
biomarkers it is difficult to assess the importance of necrotic cell death in pathological conditions
29
. 
Some of the diseases where necrosis is implicated are vascular-occlusive diseases like heart failure, brain 
damage or limb loss, cancer and neurodegenerative diseases like Alzheimer’s30. 
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1.5.2. Apoptosis 
Apoptosis is a Greek word meaning falling of leaves from a tree in the autumn. The name was first coined 
by John Kerr in 1972 and refers to the morphological feature of the formation of apoptotic bodies from a 
cell
32
. Today apoptosis is known to be a process that is both genetically and biochemically controlled in 
contrast to necrosis which is known as an accidental and functionally passive process
33
. It is a process that 
is widely known as programmed cell death. Apoptosis or programmed cell death is energy dependent and 
highly regulated and therefore not easily triggered
33
. Apoptosis is required for foetal development and 
tissue homeostasis
34
. Dysregulation of apoptosis plays an important role in diseases like 
neurodegenerative disorders, cancer and autoimmune diseases
31and 33
.    
The morphological properties of apoptosis in contrast it to necrosis include; cell shrinkage, membrane 
bebbling, partitioning of cytoplasm and nuclear contents into membrane bound apoptotic bodies and 
specific internucleosomal degradation of cellular DNA, which is the hallmark of this process
33 
. 
Apoptosis can be induced in response to developmental cues or environmental stress (e.g viral infection, 
toxicant exposure). Such an induction can take place when there is a deprivation of survival factors or 
irreparable internal damage
33 and 35
. Apoptosis can take place either through the intrinsic or extrinsic 
pathway and in either pathway the net result is cellular suicide via caspase activation
31, 33 and 34
. 
1.5.3. Apoptosis pathways 
The intrinsic pathway is also called mitochondrial pathway by some authors. Participation of 
mitochondria in apoptosis induction involves the release of caspase activating proteins into the cytosol. 
Proapoptotic Bcl-2 family members Bax and Bak translocate to the mitochondria. The BH3-only protein 
Bid activates Bax and Bak to mediate the release of cytochrome c into the cytosol. The release of 
cytochrome c leads to its binding to the Apoptotic Protease Activating Factor-1 (Apaf-1). Binding of 
cytochrome c to Apaf-1 triggers the assembly of the apoptosome (Apaf-1and caspase-9) and subsequent 
activation of the caspase- 3 and cell death. The apoptosome bound procaspase-9 is activated and can then 
activate an effector caspase like caspase -3, which then cleaves the cellular substrate needed for 
orchestring apoptosis
31, 32, 35 and 36
. An explanatory figure for both the intrinsic the extrinsic pathway, plus 
the signals involved is shown in figure 13 in page 31. 
  
 
 
 31 
 
The extrinsic pathway
 
The extrinsic pathway is also called the receptor pathway. Cell death in this pathway is initiated by TNF 
receptor super family, called death receptors (CD95, TRAIL-R1/2 and TNF-R1) after binding of their 
respective ligand (CD95L, TRAIL, and TNF). The process starts with the recruitment of adaptor proteins 
like Fas-associated death domain (FADD). This adaptor molecule has death domain (DD) on the one side 
to bind the receptor and death effector domain (DED) on the other side to bind procaspase-8. Stimulation 
of the TNF family receptor by their specific ligands results in the formation of death inducing signalling 
complex (DISC). The DISC comprises adaptor molecules like FADD and procaspase-8. The activation of 
the initiator procaspase-8 to caspase-8 propagates the apoptosis signal by direct cleavage of downstream 
effector caspases, like caspase-3. Procaspase-8 can also cleave Bid to truncated Bid which can translocate 
to the nucleus in order to activate the mitochondria pathway 
31, 32, 35 and 36.
  
. 
 
Figure 13. Apoptosis signalling pathways. These are the two important pathways of caspases activation; 
one involves the intrinsic pathway or mitochondria pathway, while the other one is extrinsic or death 
receptor pathway. The extrinsic pathway is independent of p53. 
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1.5.4. Caspases 
The name here is the short form for cysteine-containing aspartate-specific proteases. They are 
intracellular cysteine proteases that have specific substrate recognition and cleave target proteins after 
their aspartate residue. Caspases are synthesized as inactive zymogens called procaspases in the cytosol. 
They can be activated either in an autoproteolytic manner or by other caspases in a cascade
34
. 
 Caspases can be grouped according to their functionality. We distinguish between initiator and effector 
caspases. The initiator caspases are characterised by their long prodomain with more than 90 amino acids 
containing either DED domains, like is the case for caspase-8 and caspase-10, or a caspase recruitment 
domain (CARD) seen in caspase-2 and caspase-9. The executioner or the effector caspases contain short 
prodomains and comprise caspase-3, caspase-6 and caspase-7
 32
.  
The remaining caspases have their main role in cytokine maturation rather than apoptosis 
32
. The initiator 
caspases are activated by autoproteolysis following the recruitment of the prodomain into multiprotein-
complexes, the effector caspases are activated by the initiator in a cascade pathway
 34
.  
Caspases are key effector molecules in apoptosis and therefore targets for pharmacological modulation in 
various diseases
42
. A high level of caspase activity leads to increased cell death. A number of diseases are 
as a result of increased levels of caspase; examples being myocardial infarction, stroke, sepsis, 
Alzheimers, Parkinson, and Huntington disease. Inhibition of caspase activity is predicted to be 
therapeutically beneficial for these diseases
42
.  Inhibition of the caspases that leads to inflammation may 
help control autoimmune diseases like rheumatoid arthritis. Lastly activation of caspases is an approach 
that can result in therapeutic treatments for cancer and chronic viral infections
42
.   
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1.5.5. Procaspase-3 and caspase-3 
Procaspases are sometimes also termed immature while caspases are said to be mature. The cleavage of 
procaspases leads to the formation of two subunits, a large and a small one, which heterodimerize and 
form the active caspase enzyme
35
. For all the caspases the active site comprises four loops L1, L2, L3 and 
L4. While L1 and L3 are well conserved structures, there is a substantial difference in both amino acid 
composition and length in L2 and L4.  The exact position of these loops is what dictates caspase substrate 
specificity
34
. 
Since caspase-3 is one of the effector caspases it exhibits a very low activity towards self activation. 
However, such activation can take place by varying the pH
37
. Other tests have also shown that caspase-3 
is more sensitive not only to pH changes but also changes in ion concentration compared to it is zymogen 
38
. A change in ionic homeostasis of the cell is one of the events leading to apoptosis.   
Under normal conditions cells have intracellular potassium concentration of ca 140 mM; this reduces to 
less than 50 mM in apoptotic cells. The decrease in intracellular potassium and the associated water 
movement are contributing factors to the change in cell volume, one of the characteristic observed in 
apoptosis. Normal potassium concentration is inhibitory to apoptosis, perhaps by acting on and inhibiting 
apoptotic nuclease. Normal potassium concentration inhibits the cytochrome c-dependent activation of 
procaspase-3, but not caspase-3. The contribution of intracellular ionic strength, which potassium has 
shown, is not unique for ion alone, but other monovalent ions give similar effects
38
.    
Caspase-3 is the mediator caspase that is ultimately responsible for the majority of apoptotic effects. In 
addition to its role in cell death, caspase-3 is also important for survival, this is evidenced by caspase-3 
knockout mice that are born at low frequency and die only a few weeks after
39
. 
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1.5.6. Inhibitors of caspase-3 
In certain pathological conditions like rheumatoid arthritis, liver injury, myocardial infarction and various 
neurodegenerative disorders, ones sees elevated levels of activated caspase-3, which is suspected to be the 
cause of the excessive cell death
40
.  Therefore, the design of caspase inhibitors has become a major 
research topic for the last 10 years. In these early studies the approach was to make a peptide or a peptide 
mimicking agents that can inactivate caspase-3. Such research has been hampered by the therapeutic 
limitation these agents have as a result of poor cell permeability, in vivo stability and bioavailability
 36, 40 
and 41
.  
To overcome such limitations one needed non peptide compounds, but these were difficult to identify and 
optimize. A series of such molecules were recently published. Isatin sulphonamides were the first ones 
described. They have shown limited selectivity for caspase-3 versus other executioner caspases
41
.  
Recently a series of aniloquinazolines (AQZs) were synthesized. They are structurally distinct from other 
none-peptide caspase-3 like isatins. The two however share an electrophilic carbonyl that certainly 
represents the site of nucleophlic attack by the active site cysteine thiolate. The AQZs are however more 
selective compared to the isatins
41
. 
A typical peptide that has caspase-3 inhibition needs the following structural characteristics: an 
electrophilic group, P1 aspartic acid, and P2-P4 peptidomimetic region. The warhead interacts with the 
cysteine residue. The warhead reversibly binds if it is one of the following; aldehyde, nitrile, or a ketone. 
If it is a methylketone it binds irreversibly
36
. The advantage reversible has against irreversible is often 
debated, but one can generally say that the irreversible warheads are effective in inflammation, while the 
reversible are effective in apoptosis. In addition the irreversible are usually said to be more specific than 
the reversibl
36
. 
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1.5.7. Activators of caspase-3 
Caspases are the key effector molecules and are therefore attractive to pharmacological modulations. 
Activation of caspase-3 is a selective approach that yields treatment for both cancer and chronic viral 
infections
 42
. Most drugs activate apoptosis by using the p53 pathway. Unfortunately in most of the cancer 
cases p53 is mutated; therefore efforts were made to bypass this upstream mutation and make molecules 
that target further downstream in the signal pathway
43
.  
An example of such downstream targeting is the inhibitors of antiapoptotic members of Bcl-2 family, 
Bcl-2 and Bcl-XL, both of which are over expressed in cancer
25
. Until recently apoptosome complex was 
not targeted. In 2003 Sunesis pharmaceuticals reported to have made compounds that promote Apaf-1 
oligomerization into a mature apoptosome, resulting in activation of procaspase-9 to caspase-9 which 
activates caspase-3
43
.  The structures are shown below in figure 14.  
These compounds can be divided into two series; the indolone series and the carbamate series. Of the 
compounds tested, one of the indolone series was the most potent in cells showing strong induction of 
caspase-3 activation, PARP cleavage, DNA fragmentation and even killing of cells with and IC50 value of 
ca 4µM
43
. 
 
     
Figure 14.  Compounds that affect on oligomerization of the apoptosome 
43
.  
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α-(trichloromethyl)-4-pyridineethanol (PETCM) is another small molecule that stimulates apoptosome 
formation and activation of caspase-3, shown in figure 15. This small molecule works by antagonising the 
effect of prothymosin-α (ProT), an oncoprotein required for cell proliferation, and enhancing the activity 
of putative HLA-DR associated protein (PHAP), a tumour suppressor protein
44.
                                          
    
       
α-(trichloromethyl)-4-pyridineethanol (PETCM)     
Figure 15. A small molecule that stimulates apoptosome formation and caspase-3 activation 
44
.     
Efforts were made to target all of the proteins in the apoptotic cascade. Examples include peptides or 
small molecules binding to p53, peptides or small molecules binding to Bcl-2 family proteins, or even the 
inhibitors of apoptosis
45
. A uniting factor for all the above targets is that they are in the early or 
intermediate positions in the apoptotic cascade. Therefore cancers with mutation in the downstream 
proteins are likely to be resistant to such attack. To make therapeutically viable molecules one needs to 
target proapoptotic proteins far downstream. Additionally if cancerous cells have higher concentrations of 
such proapoptotic protein, then this strategy would probably materialise clinically
45
. 
Procaspase activating compound (PAC-1) is a small molecule that directly activates procaspase-3 to 
caspase-3. The structure is shown in figure 16 in page 37. PAC-1 leads to chromatin condensation, 
cleavage of caspase substrate poly-ADP-ribose polymerase 1 (PARP-1), mitochondrial membrane 
depolarization and blebbling of cells
45
. Procaspase-3 is a zymogen and part of the caspase group that is 
activated by the cascade. In order for it to resist autocatalytic activation and proteolysis by caspase-9, it 
has a triaspartic acid safety catch
45
. This safety catch is sensitive to pH; upon cellular acidification the 
safety catch is thought to allow access to the site of proteolysis
 45
. The piperazine nitrogen’s of PAC-1 are 
believed to be positively charged at physiological pH and may directly interact with the triaspartic acid 
safety catch, thereby inducing the auto activation of procaspase-3 
45
. 
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Figure 16. A small molecule that directly activates procaspase-3 to caspase-3 leading to induction of 
apoptosis
45
. 
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2. Results and discussion 
 
2.1.1. Synthesis of (3-allyl-2 hydroxybenzaldehyde) (18) 
 
Figure 17. Depiction of the ortho-formylation reaction. 
The reaction depicted above in figure 17 is an ortho-formylation. The reaction was carried out under dry 
conditions and resulted easily in the formation of the preferred compound (18). A plausible mechanism 
for the reaction depicted in Scheme 1 starts with the formation of a salt in an acid-base reaction; this salt 
reacts with the paraformaldehyde and forms an alcohol, which also reacts with the paraformaldehyde in a 
redox reaction leading to the product formation
55
. The reaction mixture was purified by chromatography 
and resulted in 3-allyl-2-hydroxybenzaldehyde (18) with 69 % yield. 
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Structural elucidation of (3-allyl-2 hydroxybenzaldehyde) (18)  
A summary of the 
1
H-NMR obtained for 18 is given table 1. The singlet at 11.28 ppm is for (H-11), this is 
the least shielded proton due to the inductive effect of the oxygen. (H-10) proton is also experiencing the 
same effect and is seen at 9.87 ppm as a singlet. The next protons are the aromatic protons which are 
chemically equivalent (H-5 and 7) seen as a multiplet at 7.41 ppm. In between them comes (H-6) as a 
triplet at 6.95 ppm with J = 11.34 Hz. The aromatic protons are all observed downfield because of 
deshielding which results from the delocalized π- electrons. All three protons from the alkene moiety are 
seen as multiplets, (H-2) is assigned 5.98 ppm since the other two according to integration values come at 
5.00 - 5.08 ppm. At 4.10 ppm a quartet is seen which belongs to ethyl acetate since it was used as an 
eluting solvent
46
. Lastly (H-3) is seen as a doublet at 3.42 ppm with J = 9.84 Hz.  A summary of the 
spectrum is given below, while the whole spectrum is given in Appendix 1 in page 85. 
 
Table 1. Summary of 
1
H NMR for 3-allyl-2 hydroxybenzaldehyde (18). 
 δ  1H (ppm) Integral 
(H) 
Multiplicity  Proton          
(nr) 
 
 
 11.28 
  9.87 
  7.41 
  6.95 
  5.98 
  5.08 
  3.42 
 1  
 1  
 2  
 1  
 1  
 2 
 2   
  s 
  s 
  m 
  t               
  m 
  m 
  d                                                                                
 11 
10 
5,7 
6 
2 
1 
3
 
 
 
The carbon spectrum displays all the 10 carbons since there is no equivalency or symmetry. The 
methylene carbon (C-3) resonates at the highest upfield at 33.18 ppm. The nearest neighbour it has is the 
alkene carbon (C-1) at 116.64 ppm. The aromatic carbons are lead by (C-6 and C-8) showing their signals 
at 119.72 and 120.43 ppm respectively. The carbons (C-7 and C-4) come at 128.94 and 132.04 ppm 
respectively. To complete the aromatic carbons the last one (C-5) comes at 137.27 ppm. The second 
carbon from the alkene moiety (C-2) is detected at 136.72 ppm. The last two carbons come at downfield 
because of the deshielding from the electronegative oxygen the carbons are bearing. They are (C-10) for 
the aldehyde carbon and (C-9) for the alcohol seen at 196.86 and 159.67 ppm respectively. A summary of 
carbon spectre is shown in next page, while the  whole spectrum is given in Appendix 2 in page 85. 
 40 
 
 
Table 2. Summary of 
13
C NMR for for 3-allyl-2 hydroxybenzaldehyde (18). 
 δ  13C(ppm)     Atom (nr)          
 
 
 
 
196.86 
159.67 
120.35 
128.94 
119.72 
137.27 
131.94 
  33.18    
135.93 
116.40 
    10 
     9 
     8 
     7 
     6 
     5 
     4 
     3 
     2 
     1 
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Synthesis of ethyl 2-(4-benzylpiperazin-1-yl) acetate (21)  
 
 
Figure 18. Depiction of the ester (21) formation.  
In this is bimolecular nucleophilic substitution (SN2) reaction, see figure 18 above, the piperazine (19) 
and the ester (20) are the nucleophile and electrophile respectively, the base is used to deprotonate the 
nucleophile in order to make it stronger. In the literature this reaction was carried out using chloride ester, 
this resulted in a longer reaction time than when bromide ester was used. This could be attributed to bond 
length since the bromide has longer bond length and weaker bond strength than the chloride
47
. The 
reaction was carried out several times with isolated yields ranging from 54-67 %.  The low yield could be 
due to lack of experience considering that it was the start of the project. 
 
Structural elucidation of ethyl 2-(4-benzylpiperazin-1-yl) acetate (21) 
The methyl protons (H-1) are shown by the triplet signal at 1.24 ppm (J = 7.1Hz), since they are shielded, 
they give NMR resonance far upfield. They are neighbored by the broad signal from the piperazine 
protons (H-4, 5, 6, 7) at 2.59 and 2.52 ppm. The methylene protons attached to the piperazine (H-3, H-8) 
are shown as singlets at 3.51 and 3.18ppm, but it is difficult to decide which is which. Ethyl or methyl 
protons are usually known to appear at an upfield region between 1-3 ppm, but these an exception 
because they are attached to electronegative bearing carbons, this leads to deshielding and a signal further 
downfield. Therefore the ethyl attached to the ester (H-2) comes as a quartet at 4.16 ppm (J= 7.1 Hz). 
Lastly, we can see the benzene protons as a multiplet at 7.30 ppm and 7.28 ppm. A summary of the 
spectrum is given in the next page, while the whole spectrum is presented in Appendix 3 in page 86. 
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Table 3. Summary of 
1
H NMR for ethyl 2-(4-benzylpiperazin-1-yl) acetate (21) 
 δ 1H (ppm) Integral
(H) 
Multiplicity J 
(Hz) 
 Proton (nr) 
 
 
 
 
728 
7.30 
7.22 
3.18/3.51      
2.52/2.59 
2.52/2.59 
2.52/2.59 
2.52/2.59 
4.16              
1.24 
 
2  
2  
1  
4 
2  
2  
2  
2  
2  
3  
m 
m 
m 
s 
  brs 
brs 
brs 
brs 
  q 
 t 
 
 
 
 
 
 
 
 
7.1 
7.1 
  11, 15 
  12, 14  
  13 
   4, 9 
     8 
   7 
   6 
   5 
   2 
   1 
 
 
The 
13
C- NMR spectrum of this compound has fewer signals than the number of carbons in the 
compound, due to several carbons being in the assigned identical chemical shift values, giving fewer 
signals. To start with the aromatic ring and carbons like (C-12, C-14) are good examples to demonstrate 
such symmetry both appearing at 128.38 ppm. They are followed by their neighbors (C-11, C-15) 
appearing at 129.38 ppm. The only aromatic carbon that is neither shown as symmetrical nor as a quartet 
is (C-13) appearing at 127.22 ppm while the only quartet carbon atom (C-10) is shown at 138.21 ppm. 
The nearest signal to the aromatic ring in the upfield region is the methylene carbon (C-9) which is seen 
at 63.14 ppm, while the piperazine carbon atoms are seen at 53.25 and 52.95 ppm for ( C-5, C-7) and (C-
6, C-8) respectively. The next carbon signal is for (C-4) the methylene between the ester and the 
piperazine ring coming at 59.73 ppm, while the ester carbon (C-3) is seen at 170.47 ppm. The ethylene 
carbon (C-2) is seen at 60.74 ppm, while the methyl carbon (C-1) is shown at 14.42 ppm. A summary of 
the spectrum is given in the next page, while the whole spectrum is presented in Appendix 4 in page 86. 
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Table 4. Summary of  
 13
C NMR for 2-(4-benzylpiperazin-1-yl) acetate (21) 
 δ  13C (ppm) Atom (nr) 
 
 
 
 
129.38 
128.38 
127.22 
138.21 
   63.14 
   52.95 
   53.25 
   59.73 
 170.48 
   60.74 
   14.42 
11,15 
12,14 
13 
10 
9 
6,8 
5,7 
4 
3 
2 
1 
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Synthesis 2-(4-benzylpiperazin-1-yl) acetohydrazide (23) 
 
 
Figure 19: depiction of the hydrazine formation. 
In this synthesis ethyl 2-(4-benzylpiperazin-1-yl) acetate 21 reacted with hydrazine 22 producing 2-(4-
benzylpiperazin-1-yl) acetohydrazide 23, in a classical nucleophilic addition-elimination reaction. See 
figure 19. According to the literature
48
, the crude product is oil, which is then crystallized and further 
recrystallized to form the pure solid. In this particular synthesis the solid product formed upon using 
rotatory evaporation to remove the solvent. The product had some traces of impurities, as evidenced by 
1
H-NMR in appendix 5 on page 89. This was attributed to rest of ethanol
46
, but it was still used for further 
reaction. This experiment was also carried out in several batches resulting in isolated yields from 76-92 
%. 
Structural elucidation: 2-(4-benzylpiperazin-1-yl) acetohydrazide (23). 
The summary of the 
1
H-NMR data for this molecule is given in the next page. Starting with (H-1), the 
proton from the primary amine is not visible, due to the probability of exchanging with the water in 
chloroform. The amide proton (H-2) is seen furthest downfield at 8.10 ppm as a singlet
49
. The (H-3) 
protons are difficult to distinguish these from (H-8), but since (H-3) are neighbouring the electronegative 
amide, they will most probably be deshielded corresponding to the 3.49 ppm singlet, while (H-8) will be 
seen at further upfield at 3.06 ppm as a singlet. The piperazine protons are also difficult to distinguish, but 
they are chemically equivalent as (H-5 and H-6) and (H-7 and H-8) respectively. They are seen as broad 
signals with two peaks at 2.52 and 2.45 ppm. The remaining 5 aromatic protons are seen at 7.31 ppm as a 
multiplet, here too there is chemical equivalency following (H-9 and H-13) and (H-10 and H-12), while 
(H-11) is supposed to be seen as a singlet. A summary of the spectrum is given in the next page, while the 
whole spectrum is presented in Appendix 5 in page 87. 
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Table 5. Summary of  
1
H NMR for  2-(4-benzylpiperazin-1-yl) acetohydrazide (23) 
 
 
 
   δ   1H 
(ppm) 
Integral (H) Multiplicity  Proton (nr) 
 
 
7.29 
7.31 
7.28 
3.49/3.05 
2.52/2.45 
2.52/2.45 
3.49/3.05 
8.10 
 
2  
2  
1  
2  
4  
4  
2  
1  
 
m 
m 
m 
s 
br 
br 
s 
s 
 
 9,13 
10,12 
11 
8 
5,7 
4,6 
3 
2 
1 
 
 
The 
13
C- NMR has shown only 9 signals despite the molecule having 13 carbon atoms, due to the 
chemical shift equivalency. (C-9 and C-13) exhibit such equivalency and come at 129.32 ppm, while the 
other equivalent carbons from the aromatic ring are (C-10 and C-12) seen at 128.45 ppm. The other 
carbons with identical environments are the piperazine carbons and they are seen as (C-3 and C-5) at 
53.90 ppm, and (C-4 and C-6) are seen at 53.25 ppm. The rest of carbons are single signals due to the lack 
of identical environments. The methylene carbons both from the benzene and the piperazine are difficult 
to distinguish they are (C-7 and C-2) coming at 63.08 and 60.81 ppm. The remaining carbon of the 
aromatic ring (C-11) is seen at 127.34 ppm, while the only quartet carbon atom (C-8) is seen at 138.07 
ppm. The aldehyde carbon being much deshielded is seen farthest downfield at 170.74 ppm. A summary 
of the spectrum is given in the next page, while the whole spectrum is presented in Appendix 6 in page 
87. 
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Table 6. Summary of   
13
C NMR for 2-(4-benzylpiperazin-1-yl) acetohydrazide (23) 
 δ  13C(ppm) Atom (nr) 
 
 
 
  
129.32 
128.45 
127.34 
138.07 
  63.08 
  60.81 
  53.25 
  53.90 
170.74       
9, 13 
10, 12 
11 
8 
2/7 
2/7 
4, 6 
3, 5 
1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 47 
 
2.1.2. Synthesis of new PAC-1 derivatives 
 
Figure 20: depiction of imine formation 
In this synthesis 4-benzyl piperazino acetic acid (23) reacted with substituted salicylic aldehydes (24) 
resulting in an imine. See figure 20. The reaction time varied between 3- 48 hrs depending on the 
aldehyde. After refluxing, 
1
H-NMR was taken to both verify the product and see if recrystallization was 
needed. In all the cases the product had to be purified by recrystallization due to compound 
decomposition in silica. The isolated yields were found to be between 89-99 %.  
Structural elucidation:  
(E)-2-(4-benzylpiperazin-1-yl)-N’-(3,5-dichloro-2-hydroxybenzylidene) acetohydrazide (25). 
The product compounds all have similar 
1
H and 
13
C NMR signals with only small variations. For 
compound (25), two singlets are seen far downfield at 11.58 and 10.13 ppm, these are believed to belong 
to (H-12) and (H-16) respectively, due to the deshielding from the electronegative oxygen. The imine 
proton (H-13) appears at 8.55 ppm as a singlet. The aromatic protons appear according to the aromatic 
ring they belong. While those belonging to the benzene ring are shown as a multiplet at 7.30 ppm, the 
other two belonging to the phenol ring are shown as singlets at 7.37 and 7.11 ppm. The methylene 
protons (H-6, H-11) are shown as singlets at 3.54 and 3.18 ppm though it is difficult to exactly assign 
which is which.  The same case applies to the piperazine ring appearing as a broad signal having two 
peaks at 2.62 and 2.53 ppm. A summary of the spectrum is given in the next page, while the whole 
spectrum is presented in Appendix 7 in page 88 
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Table 7. Summary of 
1
H NMR for (E)-2-(4-benzylpiperazin-1-yl)-N’-(3,5-dichloro-2-
hydroxybenzylidene) acetohydrazide  (25)  
 δ  1H (ppm) Integral 
(H) 
Multiplicity  Proton (nr) 
 
 
 
 
11.58 
 7.37 
 7.11 
 8.54 
10.13 
  3.54 
  3.18 
  2.62 
  2.53 
  7.30   
  7.30   
1  
1  
1  
1  
1  
2 
2  
4 
4  
2                
2 
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s 
s 
s 
s 
s 
s 
br 
 br 
 m 
 m 
16 
15 
14 
13 
12 
6, 11 
6, 11 
(7, 9/8,10) 
(7,9/8, 10) 
 2, 5 
 3, 4 
                                                 
The carbon spectrum does not display 20 signals for the 20 carbons signals due to symmetry. All the 
aromatic carbons have their signals between 127.83-131.83 ppm with the exception of (C-15, C-18 and 
C-20) that has their peaks at 119.62, 123.10 and 153.32 ppm respectively. The rest of atoms are easily 
assigned, with the piperazine ring giving its peaks at 53.21 and 53.89 for (C-8, 10) and (C-9, 11) 
respectively. These are neighbored by the upfield methylene carbons of (C-7, 12) coming at 63.12 and 
61.25 respectively.  The imine carbon (C-14) is downfield at 149.52 ppm, while the amide carbon (C-13) 
is seen at 166.62 ppm. A summary of the spectrum is given in the next page, while the whole spectrum is 
presented in Appendix 8 in page 88. 
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Table 8. Summary of 
13
C NMR for (E)-2-(4-benzylpiperazin-1-yl)-N’-(3,5-dichloro-2-
hydroxybenzylidene) acetohydrazide  (25) 
Structural elucidation:  
(E)-2-(4-benzylpiperazin-1-yl)-N’-(2-hydroxy-5-nitrobenzylidene) acetohydrazide (26) 
For this compound, the 
1
H NMR spectrum is similar to compound 25, but with a few variations. The two 
most downfield signals are almost similar coming at 11.87 and 10.20 ppm and belong to the amide and 
alcohol proton respectively. The next signals are singlets at 8.58, 8.17, 8.16 and 7.06 ppm for (H-13, H-
16, H-15, and H-14) respectively. Next to these is the benzene ring whose signals occur in the aromatic 
region of as a multiplet at 7.30 ppm and integrate for 5 protons. In addition to that, the piperazine ring has 
its signals far upfield and appears as a broad peak containing all the 8 protons with chemical shifts at 2.63 
and 2.53 ppm. This means that they occur as two sets of four protons showing equivalency and 
environmental likeliness. Lastly, one can see the methylene protons at 3.54 and 3.20 ppm are (H-6 and H-
11), though it is difficult to ascertain which signal belongs to which proton. A summary of the spectrum is 
given in the next page, while the whole spectrum is presented in Appendix 9 in page 89. 
 
 
 
 
 
 δ  13 C(ppm) Atom (nr) 
 
 
 
 
 
 153.32 
 131.83 
 119.62 
 149.51                  
166.61 
  61.25 
  53.21 
  53.89 
  63.12 
20 
18 
15 
14 
13 
12 
8, 11 
9, 10 
7 
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Table 9. Summary of 
1
H NMR for (E)-2-(4-benzylpiperazin-1-yl)-N’-(2-hydroxy-5-nitrobenzylidene) 
acetohydrazide (26) 
 δ
   1
H (ppm) Integral 
(H) 
Multiplicity  Proton (nr) 
 
 
 
 
10.20 
 8.17 
 8.16 
 7.06 
 8.58 
11.87 
 3.20 
 3.54 
 2.53/2.63 
 2.53/2.63 
 7.30 
1  
1  
1  
1  
1  
1 
2  
2 
4  
4 
5              
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  s 
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  17 
16 
15 
14 
13  
12 
6, 11 
  6, 11 
(7,9/8,10) 
(7,9/8,10) 
 1-5 
 
Concerning the 
13
C
 
NMR spectrum the compound has 20 carbons but due to symmetry only 16 signals 
were seen. The carbon resonating at farthest downfield is the aldehyde (C-13) with its signal at 166.47 
ppm, while its nearest neighbor is no doubt from the hydroxyl carbon (C-20) coming at 163.97 ppm. 
Following these is the imine carbon (C-14) at 148.91 ppm. With the exception of (C- 4) seen at 140.56 
ppm, the rest of carbons from the benzene ring are seen between 126.99 -129.41 ppm, together with some 
of the carbons from the phenol ring. Those from the phenol ring not seen in that interval are (C-15 and C-
19) seen at 118.26 and 117.44 ppm respectively. Remaining then are the methylene and the piperazine 
carbons. They are seen further upfield neighboring signals. The methylene are the first, appearing at 62.97 
and 61.05 ppm for (C-7 and C-12) respectively, while the piperazine signals are symmetrical for (C-8, 11) 
and (C-9, 10) at 53.07 and 53.81 ppm respectively. A summary of the spectrum is given in the next page, 
while the whole spectrum is presented in Appendix 10 in page 89. 
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Table 10. Summary of 
13
C NMR for (E)-2-(4-benzylpiperazin-1-yl)-N’-(2-hydroxy-5-nitrobenzylidene) 
acetohydrazide (26) 
 δ  13C (ppm) Atom (nr) 
 
 
 
163.97 
117.44 
118.26 
148.91 
166.47  
  61.05 
  53.81 
  53.07 
  62.97 
20 
19 
15 
14 
13 
12 
8,11 
9,10 
7 
 
 
Structural elucidation for (E)-2-(4-benzylpiperazin-1-yl)-N’-(3,5-dibromo-2-hydroxybenzylidene) 
acetohydrazide (27). 
The 
1
H-NMR spectrum of this compound has similar features with the other compounds. One can see the 
fast pattern that is seen for all the other compounds. To start with, the far most downfield signal belongs 
to the amide hydrogen (H-12) at 11.73 ppm .To its right side one can see the phenol proton (H-16) with 
its shift value of 10.13 ppm as a singlet. Following these is the imine proton (H-13) as a singlet at 8.50 
ppm. The benzene ring and the phenol ring have their protons between 7.28-7.66 ppm both as a doublet 
and as a multiplet. Upfield one can figure the singlets at 3.54 and 3.18 ppm for the methylene protons (H-
6 and H-11) even though we cannot be certain which one belongs where. Lastly the piperazine protons 
are seen as two peaks at 2.62 and 2.52 ppm for (H-8, 10) and (H-7, 9). A summary of the spectrum is 
given in the next page, while the whole spectrum is presented in Appendix 11 in page 90. 
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Table 11. Summary of 
1
H NMR for (E)-2-(4-benzylpiperazin-1-yl)-N’-(3,5-dibromo-2-
hydroxybenzylidene) acetohydrazide (27) 
     δ  1H (ppm) Integral      
(H) 
   Multiplicity  Proton (nr) 
 
 
 
 
 
 
  10.13 
    7.30 
    7.66 
    8.50 
   11.73 
     2.62 
     2.52             
    3.18 
    3.54 
    7.29 
    7.28 
    7.28 
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(7, 9/8,10) 
(7, 9/8,10) 
(6, 11) 
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(2, 5) 
(3, 4) 
  1 
    
The 
13
C
 
NMR spectrum is showing the typical characteristic of symmetry. That implies not all the carbon 
signals are shown one by one but some signals represent more than one carbon. The signal residing 
farthest downfield belongs to the aldehyde showing at 166.50 ppm. Close to the aldehyde comes the 
phenol carbon shown at 154.50 ppm. This is followed by the imine at 149.16 ppm. The carbons for both   
benzene ring and the phenol ring are seen at the typical benzene ring region between 120-140 ppm. Here 
the exceptions are (C-17 and C-19) seen at 112.21 and 110.98 ppm, respectively. The only carbons 
remaining belong to the piperazine and the methylene carbons. The methylene carbons are seen first and 
are also showing symmetry meaning all of them are not shown. Their signals appear at 63.07 and 61.19 
ppm for (C-7 and C-12) respectively. The piperazine carbons have symmetry meaning only two signals 
are detected for the four carbons; (C-8 and C-11) have peaks at 53.17 ppm, while (C-9 and C-10) are 
appearing at 53.95 ppm. A summary of the spectrum is given in the next page, while the whole spectrum 
is presented in Appendix 12 in page 90. 
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Table 12. Summary of 
13
C NMR for (E)-2-(4-benzylpiperazin-1-yl)-N’-(3,5-dibromo-2-
hydroxybenzylidene) acetohydrazide (27) 
 δ  13C(ppm) Atom (nr) 
 
 
 
 
 
 
154.50 
110.98 
112.21 
149.16 
166.50 
  61.19 
  53.17 
  53.95 
  63.07 
20 
19 
17 
14 
13 
12 
8,11 
9,10 
7 
 
 
Structural elucidation:  
(E)-2-(4-benzylpiperazin-1-yl)-N’-(3-bromo,5-chloro-2-hydroxybenzylidene) acetohydrazide (28) 
The 
1
H NMR spectrum of 28 is also similar to the other compounds. One can see the same pattern as the 
others. To start with the far downfield signals at 11.71 and 10.15 ppm belong to the amide and phenolic 
protons of (H-12 and H-16) respectively. The imine proton of (H-13) is seen not far from the two at 8.52 
ppm. The seven aromatic protons are shown in the aromatic region between 7-8 ppm. Farther upfield one 
can see the methylene protons of (H-6 and H-11) as singlets at 3.54 and 3.18 ppm. Lastly we can see the 
piperazine protons as a broad signal containing the symmetrical protons of (H-7, 9 and H-8, 10) at 2.62 
and 2.53 ppm. A summary of the spectrum is given in the next page, while the whole spectrum is 
presented in Appendix 13 in page 91. 
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Table 13. Summary of 
1
H NMR for (E)-2-(4-benzylpiperazin-1-yl)-N’-(3-bromo,5-chloro-2-
hydroxybenzylidene) acetohydrazide (28) 
 δ  1H (ppm) Integral 
(H) 
Multiplicity  Proton (nr) 
 
 
 
 
10.15 
  7.53 
  7.52 
  8.52 
 11.71 
  3.54 
  3.18 
  2.62 
  2.53 
 7.30 
 7.30 
 7.16           
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 (2, 5) 
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 1 
 
 
The 
13
C
 
NMR spectrum is also not very different from the other compounds. Farthest downfield we can 
see the aldehyde carbon (C-13) at 166.37 ppm. Close to the aldehyde comes the phenol carbon shown at 
154.02 ppm. This is followed by the imine at 149.21 ppm. The carbons for both benzene and the phenol 
ring are seen at the typical benzene ring region between 120-140 ppm, here the exception is (C-19) seen 
at 111.80. The only carbons remaining now belong to the piperazine and the methylene carbons. The 
methylene carbons are farther upfield are also showing symmetry meaning all of them are not shown. The 
methylene carbons are (C-7) at 62.89 ppm and (C-12) at 61.01 ppm. The piperazine are (C-8, 11) having 
peaks at 52.99 ppm, while (C-9, 10) are shown at 53.61 ppm. A summary of the spectrum is given in the 
next page, while the whole spectrum is presented in Appendix 14 in page 91. 
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Table 14. Summary of 
13
C NMR for (E)-2-(4-benzylpiperazin-1-yl)-N’-(3-bromo,5-chloro-2-
hydroxybenzylidene) acetohydrazide (28) 
 δ  13C(ppm) Atom (nr) 
 
 
 
154.02 
111.80 
149.21 
166.37 
  61.01 
  52.99 
  53.61 
  62.89 
20 
19 
14 
13 
12 
8,11 
9,10 
7 
    
 
 
Structural elucidation: 
(E)-N`-(3-allyl-2-hydroxybenzylidene)-2-(4-benzylpiperazin-1-yl) acetohydrazide PAC-1(16). 
This structure was elucidated before by Hergenrother et al. in late 2006. It starts as usual with the 
aldehyde and the phenol as singlets at 11.17 and 9.95 ppm respectively. The characteristic feature of the 
other compounds continues until the imine proton is visible at 8.35 ppm as a singlet. From there this 
molecule has shown distinct pattern with the following signals. The aromatic protons are shown as 
complicated multiplets and it is difficult to assign which is which. The alkene moiety has a clear signal 
with two of its protons coming close to one another at 4.96 ppm and 5.05 ppm, while the third one is seen 
at 5.96 ppm as a doublet of a doublet since it couples with the methylene and the other alkene protons. 
The methylene protons are also seen clearly with the downfield signal belonging to the methylene 
between the piperazine and the benzene, while the one next to it is for the other methylene of the 
piperazine. The last of those signals belongs to the methylene of the phenol. The signal at the highest 
upfield belongs to the eight piperazine protons.  A summary of the spectrum is given in the next page, 
while the whole spectrum is presented in Appendix 15 in page 92. 
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Table 15. Summary of 
1
H
 
NMR for (E)-N’-(3 allyl-2 hydroxybenzylidene)-2-(4-benzylpiperazin-1-yl) 
acetohydrazide (16) 
 δ  1H (ppm) Integral 
(H) 
Multiplicity  Proton (nr) 
 
 
 
 
 
 
 9.95 
 5.00 
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 3.11 
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 6.81 
 7.02 
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 2.46 
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The carbon spectrum is shows expected signals for the compounds synthesized; at the same time it also 
shows the signals typical for this compound. There is no doubt that the two signals at farthest downfield 
belong to the aldehyde and the phenol respectively. They are followed by the imine carbon at 151.33 
ppm. What follow these are the aromatic carbons stretching between 115.80 and 137.87 ppm. On the 
other side of the chloroform signal we first figure the signals belonging to the methylene carbons, which 
are followed by the signals of the pyridine ring. The last signal belongs to the methylene of the phenol, 
while the alkene signals come in the alkene region between 120-140 ppm. A summary of the spectrum is 
given in the next page, while the whole spectrum is presented in Appendix 16 in page 92. 
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Table 16. Summary of 
13
C
 
NMR for (E)-N’-(3-allyl-2 hydroxybenzylidene)-2-(4-benzylpiperazin-1-yl) 
acetohydrazide (16) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 δ  13C(ppm) Atom (nr)  
 
 
 
 
115.80 
136.64 
  33.99 
156.51 
117.02 
151.33 
165.99 
  61.10 
  52.80 
  53.82 
  63.00 
23                             
22 
21 
20 
15 
14 
13 
12 
8, 11 
9, 10 
7 
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2.1.3. Efforts to synthesize other PAC-1 derivatives 
 
 
Figure 21: depiction of the imine with boronic acid derivate 
The reaction depicted in figure 21 was also attempted. Generally it is similar to the reactions that resulted 
in compounds 16, 25-28. The idea behind the reaction was if the phenol moiety is important and part of 
the pharmacophore then creating a boronic acid moiety would fulfil that function. Under the same 
conditions for the previous reactions, the product was formed after 4 hours. As was the case for the other 
products this one too had be to recrystallized, after trying several solvents both in one solvent and two 
solvent methods, the product was still not pure and the process was therefore stopped.  
 
 
   
  
Figure 22: depiction of the ester reduction 
The reaction shown in figure 22 was also attempted. In the literature a similar ester was reduced using the 
same conditions 
50
. It is a standard reduction reaction with lithium aluminium hydride reducing an ester to 
an alcohol. This was to be followed by oxidizing the alcohol to the desired aldehyde. The first step of the 
reaction was unsuccessful, leading to discarding the idea.   
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2.1.4. Biological testing  
A total of 5 new compounds were synthesised including PAC-1 as positive control. An overview of the 
compounds is shown in Figure 23. With the biological results from in-vitro testing, the potency of these 
compounds compared to PAC-1 can be ascertained/ evaluated. The biological testing further elucidates 
the structural activity relationship of the compounds.  
 
 
 
Figure 23: structures of the synthesized compounds that were subjected to biological testing.  
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The compounds have two variations. The first group has halogen substituents on the phenol, see figure 23 
for the structures of 25, 27, and 28 representing the halogens. While the other variation with a nitro group 
on the phenol is shown in figure 23 as compound 26. PAC-1 shown as compound 16 in figure 23 was 
used as control. A 96 wells plate with PC-12 cells was used for the detection of cell viability. Here the 
cell viability was determined for the concentration interval 0.3-100 mM. For a detailed description of 
method see the experimental part of the thesis on page 79.  
The biological test done on these molecules is an in-vitro test with the aim of determining cell viability 
meaning how many cells survived after subjected to the treatment of the compounds. The in-vitro testing 
was done in collaboration with Professor Ragnhild Paulsen and her group. From these biological tests, the 
compounds were all seen to reduce cell viability. The average result from three experiments will be 
reported and discussed below. The result is showing is how each molecule is able to reduce cell viability. 
On the other hand these results do not explain the exact pharmacological process that has taken place. In 
order words the result can point to something that is to be subjected to further studies. 
The following graphs in figure 24 are the percent effect in cell viability in Y axis and concentration in X-
axis. The graphs were made from mean of the three experiments, and concentration interval of 0.3, 1, 3, 
10, 30 and 100 mM was used to determine the percentage of cell viability shown in the graphs. Each 
graph represents a compound, and the overview of the compound concerned is shown in the figure 23.  
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  a) 
 
        b)  c) 
  d)   e) 
Figure 24: the graphs a, b, c, d and e which are for the test compounds are showing the 
percentage  cell viability the cells have when subjected to compounds 16, 25, 26, 27 and 28 
respectively. DMSO (0, 1%) was used as negative control. The compounds were subjected to the 
cells for 48 hours, before an MTT assay was run. The data represent the average ± Standard 
deviation (n= 3). 
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Figure 24 a, b, c, d and e shows the percentage cell viability for compounds 16, 25-28 in different 
concentrations. The effect is measured as the number of cells viable after a certain time of treatment with 
the compounds. Such an effect is measured in percentage. Concentration interval of 0, 3 - 100 mM of 
every compound was used in the experiment, and data from all the measurements will be presented.  
The graphs in Figure 25 are meant to highlight how each compound reduces cell viability in comparison 
with PAC-1. Graphically one can see that the halogen compounds are almost overlapping with PAC-1, 
while the graph representing the nitro compound is slightly higher than PAC-1 in cell viability tests. This 
indicates that the percentages of cells viable when treated with the nitro compound are higher than both 
those treated with PAC-1 and any of the compounds with the halogens.  
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 a)  b) 
c)  d) 
 
 
Figure 25: the graphs a, b, c and d represent compounds 25, 26, 27and 28 respectively. The graphs are 
plotted using the same data as the graphs in figure 24. The axis have even the same denominator, but the 
difference here is that each and every compound is plotted and shown in the same figure with the positive 
control compound here named as compound 16. The data represent the average ± Standard deviation (n= 
3). 
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2.1.5. PAC-1 and its derivates reduce cell viability.    
Taking the graphs in Figure 24 and 25 into consideration one can clearly see that all the compounds are 
leading to cell death. The compounds are all having IC50 values equal or similar to PAC-1, with the 
exception of the compound with the nitro group.  
 
 
Compound structure IC50 value 
 
 
 
 
 
 
 
 
 
 
3-10 mM 
 
 
3-10 mM 
 
 
20-30 mM 
 
 
3-10 mM 
 
 
3-10 mM 
 
Table 17:  overview of the compounds with their respective IC50 values. 
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2.1.6. Discussion  
Taking the graphs shown in figure 24 and 25 into account, we can conclude that all the compounds are 
effective in reducing cell viability. The nitro group shows lower potency compared to the other 
compounds. The results show that the phenol moiety is important for the activity of the compounds. 
Comparison of all the compounds clearly indicates that the substituent on the phenol moiety is a good 
indicator of the activity and/ or potency of the compound. 
There several ways of increasing the potency a lead compound. One can do homologation, meaning 
increasing the number hydrophobic groups. Others ways include chain branching, ring transformation and 
even adding bioisosteric groups
51
. The last measure was applied here. Use of bioisosteric group can lead 
to changes in many features within the molecule. The pharmacological and even pharmacokinetic 
properties can be altered. In this case the aim was to change the pharmacological aspects in order to get 
more potent products.     
There are three hypotheses about the mechanism of action of these compounds; the first one suggested by 
Hergenrother et.al.is one that the cleavage of procaspase-3 to caspase-3 takes places when its released 
from it is safety catch. Releasing from the safety catch occurs only when there are acidic conditions. The 
piperazine ring is believed to be acidified at normal pH. Such acidification is dependent on the 
substituents. This implies that when there are strongly electrons withdrawing groups like nitro, the 
inductive effect is reduced; hence the piperazine ring would not take up a proton, in contrast to when 
there are weakly electron withdrawing groups like the halogens. 
The second hypothesis concerning the mechanism of action is that the phenol ring is important either by a 
hydrogen binding with the imine or of acidification of the safety catch and hence conversion of 
procaspase-3 to caspase-3. We think the latter is what happens due to the analysis of the other 
substituent’s of the phenol ring; one can see the stronger electron withdrawing the substituent is, the less 
potent the compound and vice versa.  
In 2001, a review article by Tran et al. discusses the role of zinc in caspase activation and apoptotic cell 
death. Substantial evidence has linked Zn deficiency with increased susceptibility of cells and tissues to 
die by apoptosis. The pool of Zinc with such effects on apoptosis is the more exchangeable (labile) Zn, 
which are also readily depleted in Zn deficiency and augmented following Zn supplementation
51
. 
Caspase-3 was found to be insensitive to exogenous Zn when a metal chelator and thiol reducing agent 
were used. This was attributed to the fact that Zn can bind to the chelator and hence lower concentration 
of Zn to inhibit the caspase. However using a cell-free system with PARP and caspase-3, Zinc was found 
to inhibit PARP proteolysis by caspase-3 in µM range
51
.  
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Recently Hergenrother et al. reported a third hypothesis that zinc is important since zinc an inhibitor of 
procaspase-3. When PAC-1 enters the cells it competes for the labile zinc pool, reducing the level of zinc 
available to inhibit procaspase-3. This results in auto activation of procaspase-3 to caspase-3 when it is 
liberated. With the generation of caspase-3 more substrates are cleaved and apoptosis occurs 
52
. 
According to SAR studies by Hergenrother and his group, PAC-1 was effective in inducing both 
procaspase-3 activation and cell death in cancer cell cultures with IC50 and EC50 of 0.22 and 0.92 µM 
respectively. Of all the other compounds they tested, the derivative lacking the allyl was also able to 
induce activation of procaspase-3 and cell death at levels similar to those induced by PAC-1. What these 
two compounds have in common that is lacking in the other derivatives is the phenolic hydroxyl and the 
benzyl moiety. 
In our group SAR was done for PAC-1 derivatives with electron withdrawing groups. By substituting the 
allyl, which is electron donating, with an electron withdrawing group like halides; one makes the phenolic 
hydroxyl more acidic, leading auto catalysation of procaspase-3 to caspase-3 and eventually cell death. 
The compounds with a single halogen substitution show cytotoxicity effects, increasing the number of 
halogens to increase the potency of the compounds was thought to materialise.   
 While the halogen substituted derivates show the same activity as PAC-1, the nitro derivative is four 
times lower. This can be attributed to resonance stabilization of the nitro group, which makes it hard for 
the hydrogen bond to be broken, in order to increase the acidity of the safety catchment. Thus there is not 
as much procaspase-3 conversion to caspase-3. Another reason why this compound is less active than all 
the rest is because it is more hydrophilic, with estimated log P of 0.62 this would lead to problems 
penetrating the cell membrane. The compound is localized in aqueous instead of the active site, rendering 
it inactive. 
In this master thesis, the compounds were not tested for the cleavage of procaspase-3 to caspase-3. The 
only tests done on these compounds were cell viability test by using MTT. If cell death tests because of 
caspase activating molecules were to be carried out, the experiment had to have a caspase inhibitor in 
order to exactly decide that the compounds with caspase activating properties lead to cell death. The MTT 
test is done to measure the mitochondrial activity in viable cells. By using spectrophotometry the assay 
provides rapid and reproducible results. The disadvantage with assay is it provides no morphological 
information, and its lack of ability to distinguish reversible mitochondrial impairment and injury from cell 
death
56
. 
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In that connection it is natural that one considers other types of assays.  There are few other examples like 
lactate dehydrogenase (LDG). It is based on the principal that cell death processes eventually lead to an 
increase in membrane permeability, allowing the release of cytoplasmic enzymes. Both tryptan blue and 
propidium iodide assays are based on the same principal of membrane permeability. However the tryptan 
blue and propidium iodide quantify the extent to which cells are unable to exclude these two dyes from 
their cytoplasm. Tryptan blue although not automated and time consuming is gold standard for assaying 
viability. Propidium has an advantage over tryptan blue that its calometric change can be automated
56
.   
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3.  Conclusion and further studies 
The preparations of the compounds in figure 16 were achieved with high overall yields. Due to 
decomposition on silica, all of them were purified by recrystallization. In testing the compounds for 
biological activity, PC-12 cells were used. However all the compounds have shown activity in reducing 
cell viability. What was not elaborated in this thesis is how the mechanism behind the compounds 
reducing cell viability.   
The biological tests done on the compounds have shown that the compounds all lead to reduction of cell 
viability. There is however, a variation of potency among the compounds with the compounds with 
halogen substituent’s giving a reduction in cell viability almost the same as PAC-1, while the one with the 
nitro substituent was almost in active.  
Concerning the mechanism of activation, there are currently three suggested ways these compounds can 
lead to cell death. Whether it is only one mechanism or a synergy of all three is what needs to studied 
further. Further studies should also focus on a way of increasing the potency of the compounds and 
should subject them to further biological studies that will tell us values like EC50. 
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4. Experimental 
4.1.1. General synthesis 
All the chemicals used were commercially available with analytical quality of (p.a, puriss or purum) and 
were delivered from Sigma-Aldrich. With the exception of one experiment carried out under dry 
conditions all reactions were refluxed, some were purified by chromatography while those decomposing 
in silica were recrystallized. Nitrogen for working in inert atmosphere was used as delivered from AGA. 
4.1.2. Apparatus    
The compounds were analyzed with the aid of TLC, 
1
H-NMR, 
13
C-NMR and melting point. LC-MS 
analysis was out carried for the final products 
NMR 
1
H-NMR and 
13
C-NMR spectra were recorded on a Bruker Avance DPX 300 instrument at 300 MHz for 
1
H-NMR and 75 MHz for 
13
C-NMR at 25°C. The spectres were processed in MestreNova and CDCl3 was 
used as reference. Chemical shift (δ) is given in ppm relative to the solvent CDCl3 (7.24 ppm for 
1
H-
NMR, 77.0 ppm for 
13
C-NMR). 
LC-MS 
LC-MS experiments were done using Agilent technologies liquid chromatograph 1200 series connected 
to an Agilent technologies ion trap mass spectrometer 3610 series. The instrument was further devised 
with an Agilent technologies auto sampler. In order to process the data Agilent LC-MS trap software 5.3 
was used. Gradient mobile phase was used. 
The sample was injected by using the auto sampler. The column was Eclpise CDB, C-18 packed with 
particles at 5 µm and was 4.6 x 150 mm. The compounds were detected in the MS with TIC (total ion 
currence) and EIC (extracted ion currence).  The amount injected was 1-2 uL, the flow rate was 0.8 
ml/min with varying total chromatography time between 10-20 minutes. The maximum pressure was set 
to be 400 bar, while the temperature was 25°C. The UV absorption had a wave length of 254 nm.  
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Melting point 
The melting point was measured for the final products. The instrument used was Barnstead 
Electrothermal 9200 with capillary size of 100 x 2 mm from Electrothermal. A minimum of 2 parallels 
were taken for each compound. The melting points are all uncorrected.  
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4.1.3. Synthesis of intermediates 18, 21 and 23 
Synthesis of 3-ally- salicylicaldehyde (18) 
A 250 mL round bottom flask was charged with 4.6 g (48 mmol) magnesium chloride. To this was added 
2.2 g (72 mmol) paraformaldehyde and 150 mL tetrahydrofurane through a syringe. To the mixture 6.7 
mL triethylamine was also added with the aid of a syringe. After stirring for 10 minutes, a color change 
from white to purple was observed. To all these, 3.2 g (24 mmol) allyl phenol was added. The mixture 
was then immersed in an oil bath with a temperature of 75 ⁰C. The heating was maintained for 3.5 hours 
and TLC analysis indicated the aldehyde formation was complete. The reaction mixture was cooled to 
room temperature before 60 mL of ether was added. The mixture was washed with 1 N HCl (3x 60 mL) 
and later with the same amount of water. The organic phase was dried over MgSO4, filtered and solvent 
evaporated. The crude product was purified by flash chromatography (H. 50 cm, diameter 0.5 mm) with 
ethyl acetate and hexane as eluting solvents in the ratio 1:9. The vials containing traces of product after 
TLC analysis were pooled together in a round bottomed flask and the solvent evaporated. The yield was 
found to be 69 % of 3 allyl salicylicaldehyde.
  
1
H-NMR (CDCl3, 300 MHz): δ 11.28 (s, 1H), 9.87 (s, 1H), 7.41 (m, 2H), 6.95 (t, 1H), 5.98 (m, 1H), 5.08 
(m, 2H), 3.42 (d, 2H) ppm.  
13
C- NMR (CDCl3, 75 MHz): δ 196.86, 159.67, 137.27, 135.93, 131.94, 128.94, 120.35, 119.72, 116.40, 
33.18 ppm. 
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Synthesis of ethyl (4-benzylpiperazino) acetate (21) 
A 250 ml round bottomed flask was charged with 5 g (28.5 mmol) 1-benzylpiperazine, 3.0 g (35.7 mmol) 
NaHCO3, and 57 mL of acetone. To the stirring solution 5.3 g (31.6 mmol) of ethyl bromoacetate was 
added dropwise for a period of 2 minutes. The reaction was refluxed for 22 hours before TLC analysis 
was performed with the following system hexane:ethyl acetate 1: 4  and showed that the  reaction was 
complete. The solution was filtered and the insoluble salts washed with acetone. Another TLC was taken 
to determine the ∆Rf as 0.49. The solvent in the reaction mixture was evaporated and an oily remnant was 
applied to a silica column, flashed a gradient eluting system consisting of hexane:  ethyl acetate 1: 1 and 
hexane: ethyl acetate 1: 4. The product was concentrated after the flash to afford 4.45 g (60 %) of ethyl (4 
–benzylpiperazino) acetate 20 as a yellow liquid. The same experiment was done for two other batches 
and yields were between 54% and 58.%.  
1
H-NMR (CDCl3, 300 MHz): δ 7.30 (m, 2H), 7.28 (m, 2H), 7.22 (m, 1H), 4.16 (q, 2H), 3.51 (s, 2H), 3.18 
(s, 2H), 2.59 (br, 4H), 2.52 (br, 4H), 1.24 (t, 3H).
   
13
C- NMR (CDCl3, 75 MHz): δ 170.48, 138.21, 129.38, 128.38, 127.22, 63.14, 60.74, 59.73, 53.25, 
52.95, 14.42 ppm 
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Synthesis of 2-(4- benzylpiperazino-1-yl) acetatohydrazide (23)
 
A 250 mL round-bottom flask was charged with 4.75 g (18.1 mmol) of ethyl (4- benzylpiperazino) 
acetate (20) and 25 mL of ethanol. After adding 2.76 mL (50 mmol) hydrazine dropwise over a period of 
2 minutes, the reaction was refluxed for 16 hrs. The mixture was concentrated via rotatory evaporation 
after TLC assessment showed the reaction as complete. The yellow liquid formed after distillation was 
transferred to a separatory funnel containing 20 mL of 1:1 brine: H2O made basic with NaOH (pH> 12).  
The aqueous layer was extracted with three 15 mL portions of CH2Cl2 and one 15 mL portion of EtOAc. 
The organic layers were pooled together, concentrated to yellow oil and combined with 5 mL hot ethanol, 
then slowly mixed with anhydrous diethyl ether. The formation of only a few crystals brings the idea of 
evaporating the solvent in order to retrieve the product. After washing the crystals with cold hexane, the 
result was 4.106 g (91.3 %) of (4- benzylpiperazino) acetic acid hydrazide (22). This reaction was also 
carried out in several other batches since a substantial amount of these intermediate was required further 
in the project. The yield in those other synthesis was 76 % as isolated yields. 
 1
H-NMR (CDCl3, 300 MHz): δ 8.10 (s, 1H), 7.31 (m, 2H), 7.29 (m, 2H), 7.28 (m, 1H), 3.49 (s, 2H), 3.05 
(s, 2H), 2.52 (br, 4H), 2.45 (br, 4H).  
13
C- NMR (CDCl3, 75 MHz): δ 170.74, 138.07, 129.32, 128.45, 127.34, 63.08, 60.81, 53.90, 53.25. 
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4.1.4. Synthesis of the products 16, 25, 26, 27 and 28 
Synthesis of (E)-N`-(3-allyl-2-hydroxybenzylidene)-2-(4-benzylpiperazin-1-yl) 
acetohydrazide.(16) 
A 100 mL round bottomed flask was charged with 0.26 g (1.63 mmol) of 3-allyl salicylicaldehyde and 2 
mL of ethanol. To the stirring solution, 0.49 g (1.98 mmol) of (4-benzylpiperazino) acetic acid hydrazide, 
8 mL of ethanol and 10 µL of 12M HCl as catalytic amount were added. The reaction was heated at 
reflux for 46 hrs. The reaction mixture was concentrated to form a solid that was recrystallized with 1:15 
ethanol: hexane to afford 0.64 g (94 %) PAC-1 as white solid.  
1
H-NMR (CDCl3, 300 MHz): δ 11.17 (s, 1H), 9.95 (s, 1H), 8.35 (s, 1H) 7.12 (m, 8H), 6.81 (t, 1H), 6.02 
(dd, 1H), 5.05 (dd, 2H), 3.48 (s, 2H), 3.39 (d, 2H), 3.11 (s, 2H), 2.54 (br, 8H).  
13
C NMR (CDCl375 MHz): δ 165.99, 156.60, 137.84, 136.70, 132.47, 128.52, 127.45, 119.23, 117.066, 
115.83, 63.04, 61.12, 53.86, 53.17, 34.04 
Melting point: 135.6°C-136.4°C. 
LC-MS: 9.44 min. MS: m/z 393 ([M+1]) = 100 % 
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Synthesis of (E)-2-(4-benzylpiperazin-1-yl)-N`(3,5-dichloro-2-hydroxybenzylidene)  
acetohydrazide.(25) 
A 100 mL round bottom flask was charged with 0.38 g (1.97 mmol) of 3,5dichlorosalicyliclaldehyde and 
10 mL of ethanol. To the stirring solution, 0.54 g (2.17 mmol) of 4-benzylpiperazino acetic acid 
hydrazide was added with a catalytic amount (10 µl) of 1M HCl. The reaction was heated at reflux for 3 
and ½ hrs. The reaction mixture was concentrated via rotatory evaporation and the yellow solid powder 
was recrystallized with methanol to afford 0.82 g (99 %) of (E)-2-(4-benzylpiperazin-1-yl)-N’-(3, 5-
dichloro-2-hydroxybenzylidene) acetohydrazide (25) as crystals. The crystals were filtered and washed 
with cold hexane and dried in vacuum. 
 1
H-NMR (CDCl3, 300 MHz): δ 11.58 (s, 1H), 10.13 (s, 1H), 8.55 (s, 1H), 7.37 (s, 1H), 7.30 (m, 4H), 
7.11 (s, 1H), 3.54 (s, 2H), 3.18 (s, 2H), 2.63 (br, 4H), 2.53 (br, 4H). 
 
13
C NMR (CDCl375 MHz): δ 166.61, 153.32, 149.52, 131.83, 128.87, 127.83, 123.11, 119.62, 63.12, 
61.25, 53.88, 53.21. 
Melting point: 189.7°C-191.4°C. 
LC-MS: 11.35 min. MS: m/z 421 ([M+1]) = 100 % 
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Synthesis of (E)-2-(4-benzylpiperazin-1-yl)-N`-(2-hydroxy-5-nitrobenzylidene)  
acetohydrazide.(26) 
A 100 mL round bottom flask was charged with 0.165 g (0.99 mmol) of 2 hydroxy, 5 nitrobenzaldehyde 
and 5 mL of ethanol. To the stirring solution, 0.27 g (1.087 mmol) of 4-benzylpiperazino acetic acid 
hydrazide was added with a catalytic amount (10 µl) of 1M HCl. The reaction was heated at reflux for 3.5 
hrs. The reaction mixture was concentrated via rotatory evaporation and the yellow solid powder was 
recrystallized with ethanol to afford 0.393 g (94 %) of (E)-2-(4-benzylpiperazin-1-yl)-N’-(5 nitro, 
hydroxybenzylidene) acetohydrazide (26) as crystals. The crystals were filtered and washed with cold 
hexane and dried in vacuum.
  
1
H-NMR (CDCl3, 300 MHz): δ 11.87 (s, 1H), 10.20 (s, 1H), 8.58 (s, 1H), 8.17 (m, 2H), 7.30 (m, 5H), 
7.06 (d, 1H), 3.54 (s, 2H), 3.20 (s, 2H), 2.62 (br, 4H), 2.53 (br, 4H).
  
13
C NMR (CDCl375 MHz): δ 166.47, 163.97, 148.91, 140.56, 129.41, 128.57, 127.59, 127.32, 126.99, 
118.26, 117.44, 62.97, 61.05, 53.81, 53.07. 
LC-MS: 10.01 min. MS: m/z 399 ([M+1]) = 100 % 
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Synthesis of (E)-2-(4-benzylpiperazin-1-yl)-N`-(3,5-dibromo-2-hydroxybenzylidene) 
acetohydrazide.(27) 
A 100 mL round bottom flask was charged 0.55 g (1.97mmol) of 3,5- dibromosalicyliclaldehyde and 10 
mL of ethanol. To the stirring solution, 0.54 g (2.17 mmol) of 4-benzylpiperazino acetic acid hydrazide 
was added and a catalytic amount (10 µl) of 1M HCl. The reaction was heated at reflux for 3 hrs. The 
reaction mixture was concentrated via rotatory evaporation and the yellow solid powder was 
recrystallized with dichloromethane and hexane to afford 0.997 g (99 %) of (E)-2-(4-benzylpiperazin-1-
yl)-N’-(3, 5-dibromo-2-hydroxybenzylidene) acetohydrazide (27) as white crystals. The crystals were 
filtered and washed with cold hexane and dried in before an NMR was taken.
  
1
H-NMR (CDCl3, 300 MHz): δ 11.73 (s, 1H), 10.13 (s, 1H), 8.50 (s, 1H), 7.66 (d, 1H), 7.30 (s,1H), 7.29 
(m, 2H), 7.28 (m, 3H),  3.54 (s, 2H), 3.18 (s, 2H), 2.62 (br, 4H), 2.52 (br, 4H).  
13
C NMR (CDCl375 MHz): δ 166.50, 154.50, 149.16, 137.10, 132.36 129.34, 128.54, 127.48, 119.88, 
112.21, 110.98, 63.07, 61.19, 53.95, 53.17.    
Melting point: 200.8 - 202.5°C 
LC-MS: 11.18 min. MS: m/z 511 ([M+1]) = 100 %  
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Synthesis of (E)-2-(4-benzylpiperazin-1-yl)-N`-(3-bromo,5-chloro-2-hydroxybenzylidene) 
acetohydrazide.(28) 
A 100 mL round bottom flask was charged with 0.46g (1.97 mmol) of 3-bromo-5 
chlorosalicyliclaldehyde and 10 mL of ethanol. To the stirring solution, 0.54 g (2.17 mmol) of 4-
benzylpiperazino acetic acid hydrazide was added and a catalytic amount (10 µl) of 1M HCl. The reaction 
was heated at reflux for 4 hrs. The reaction mixture was concentrated via rotatory evaporation and the 
yellow solid powder was recrystallized with ethanol to afford 0.820 g (89 %) of (E)-2-(4-benzylpiperazin-
1-yl)-N’-(3-bromo-5- chloro-2-hydroxybenzylidene) acetohydrazide (28) as white crystals. The crystals 
were filtered and washed with cold hexane and dried in vacuum.
  
1
H-NMR (CDCl3, 300 MHz): δ 11.71 (s, 1H), 10.15 (s, 1H), 8.52 (s, 1H), 7.53 (s, 1H), 7.52 (s, 1H),  7.30 
(m, 4H), 7.16 (d, 1H J= 2.4 Hz), 3.54 (s, 2H), 3.18 (s, 2H), 2.62 (br, 4H), 2.53 (br, 4H). 
 
13
C NMR (CDCl375 MHz): δ 166.37, 154.02, 149.20, 134.47, 129.51, 128.62, 127.72, 124.43, 119.24, 
111.80, 62.89, 61.00, 53.61, 53.00.    
Melting point: 197.6 - 199.1°C 
LC-MS: 10.98 min. MS: m/z 467 ([M+1]) = 100 %  
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4.1.5. Methods 
4.1.6. Measuring cell viability using 96 well methods 
It was by the use of this method that the effects of the synthesized compounds were quantified in PC-12 
cells. The PC-12 cells were harvested in 96 well cell plates and incubated with the substances after a day 
of division. The substances and the cells were then left undisturbed for 48 hours, before the substances 
were removed and MTT was added for an hour, after an hour, MTT was removed and DMSO added to 
aid the wavelength measurement 
The five different compounds, 16, 25-28 were tested for their cell viability activities. For all of them a 
concentration interval of 0.3-100 mM in DMSO was used. Some of the wells were used as control and 
treated with only (0.1 %) DMSO while others were left untreated meaning. All the wells were otherwise 
subjected to the same treatment. For each substance 12 wells were used and 3 separate trials were done. 
The cells were incubated for two days when they were subjected/ treated with 100 µL of their respective 
substance. When the substances were removed after two days the cells were treated with 50 µL of MTT 
for an hour. When the MTT was removed the cells were treated with 100 µL of DMSO.   
 
4.1.7. PC-12 cells 
PC-12 cells from rat pheochromocytoma were used. They were grown in 5 % horse serum and 10 % fetal 
bovine serum. The old media was aspirated. The flask was hit to dislodge remaining cells. Serum was 
added to 10 ml of media and pipetted 5-10 times to dispense the cells. To a flask of 150 cm containing 20 
ml of media was added 2 ml of media cells. This was incubated at 37 °C with 12 % CO2.  A 96 well plate 
was used and the cell density was found to be 4000 cells per well. After 24 hours incubation the cells 
were treated with the compounds. 
 
 
 
.  
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4.1.8. Cell viability studies by using MTT 
The aim of this study was to see the effect of the five compounds and to compare them. Principal is based 
on the breakdown of tetrazoilum salt (MTT) by mitochondrial de-hydrogenases of the living cells. The 
tetrazoilum ring of MTT is cleaved and it is reduced to a blue formazan, see figure 26 below. The result is 
colour change, the intensity of which reflects the enzymatic activity of the living cells
54
.  
 
 
Figure 26: depiction of how MTT is reduced to a blue formazan. 
PC-12 cells which were newly seeded into 96 wells plate were used for the cell viability study. The 
compounds were weighed so that the final concentration was to be 100 mM. DMSO was used as solvent. 
The starting concentration was diluted from 100 to 33, 10, 3, 1, and 0.3 mM. After 24 hours incubation, 
the cells were treated with 100 µl of compounds 16, 25-28. The wells had 8 columns and each compound 
was assigned a column for it is duplicate test, while DMSO as positive control was assigned a column. 
The remaining two columns were untreated. The cells with the compounds were then incubated at 37 °C 
for two days, before the media and the compounds were removed and 50 µl of MTT added. The MTT had 
a final concentration of 5 mg/ml.  After incubating with MTT for an hour, the MTT was removed and 
DMSO was added. The cells were illuminated by UV to measure the fluorescence.  
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Appendix 1 
1
H-NMR spectrum for compound 18. 
 (3 Allyl-2 hydroxybenzaldehyde). 
 
Appendix 2 
13 
C NMR spectrum for compound 18. 
 (3 Allyl-2 hydroxybenzaldehyde). 
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Appendix 3 
1
H-NMR spectrum for compound 21. 
 (Ethyl 2-(4-benzylpiperazin-1-yl) acetate) 
 
Appendix 4 
13
C NMR spectrum for compound 21.  
(Ethyl 2-(4-benzylpiperazin-1-yl) acetate) 
 
 87 
 
 
Appendix 5 
1
H-NMR spectrum for compound 23.  
((4- Benzylpiperazino) acetic acid hydrazide)) 
 
Appendix 6 
13 
C NMR spectrum for compound 23.  
((4- Benzylpiperazino) acetic acid hydrazide). 
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Appendix 7 
1
H-NMR spectrum for compound 25.  
((E)-2-(4-benzylpiperazin-1-yl)-N’-(3,5-dichloro-2-hydroxybenzylidene) acetohydrazide). 
 
Appendix 8 
13
C NMR spectrum for compound 25 . 
((E)-2-(4-benzylpiperazin-1-yl)-N’-(3,5-dichloro-2-hydroxybenzylidene) acetohydrazide). 
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Appendix 9 
1
H NMR spectrum for compound 26.  
((E)-2-(4-benzylpiperazin-1-yl)-N’-(2-hydroxy-5-nitrobenzylidene) acetohydrazide). 
 
Appendix 10 
13
C NMR spectrum for compound 26.  
((E)-2-(4-benzylpiperazin-1-yl)-N’-(2-hydroxy-5-nitrobenzylidene) acetohydrazide). 
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Appendix 11 
1
H-NMR spectrum for compound 27 
((E)-2-(4-benzylpiperazin-1-yl)-N’-(3,5-dibromo-2-hydroxybenzylidene) acetohydrazide). 
 
Appendix 12 
13 
C NMR spectrum for compound 27.  
((E)-2-(4-benzylpiperazin-1-yl)-N’-(3,5-dibromo-2-   hydroxybenzylidene) acetohydrazide). 
 91 
 
 
Appendix 13 
1
H-NMR spectrum for compound 28.  
((E)-2-(4-benzylpiperazin-1-yl)-N’-(3-bromo,5-chloro-2-hydroxybenzylidene) acetohydrazide). 
 
Appendix 14 
13
C NMR spectrum for compound 28.  
((E)-2-(4-benzylpiperazin-1-yl)-N’-(3-bromo,5-chloro-2-hydroxybenzylidene) acetohydrazide). 
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Appendix 15 
1
H-NMR spectrum for compound 16.  
((E)-N`-(3-allyl-2-hydroxybenzylidene)-2-(4-benzylpiperazin-1-yl) acetohydrazide). 
 
Appendix 16 
13 
C NMR spectrum for compound 16. 
 ((E)-N`-(3-allyl-2-hydroxybenzylidene)-2-(4-benzylpiperazin-1-yl) acetohydrazide). 
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 Raw data from first biological testing   
CONC. COMP 25 COMP 26 COMP 27 COMP 28 COMP 16 DMSO 
100 0,1 0,2533 0,1244 0,1175 0,085 2,1134 
33 0,2444 0,9357 0,2432 0,265 0,1131 0,9098 
10 0,6063 1,4176 0,534 0,5429 0,1307 2,1538 
3 1,6974 1,771 1,3385 1,3514 1,3406 1,7727 
1 1,7646 1,5179 1,8171 1,9687 1,7032 1,9914 
0,3 1,5359 0,9253 1,659 1,7864 1,4172 1,712 
100 0,2447 0,2311 0,0701 0,124 0,0981 2,0547 
33 0,706 0,7756 0,2897 0,3017 0,1083 1,8358 
10 0,5392 1,5296 0,2824 0,3604 0,1128 1,9599 
3 1,1316 2,0668 1,4327 1,4186 1,4618 1,824 
1 1,4867 1,898 1,9028 1,7828 1,5867 1,7812 
0,3 1,338 1,5089 1,921 1,9065 1,8675 2,6437 
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 Raw data from second biological testing.   
CONC. COMP 25 COMP 26 COMP 27 COMP 28 COMP 16 DMSO 
100 0,1414 0,3156 0,1324 0,4379 0,1169 1,9478 
33 0,2108 0,6171 0,3663 0,3446 0,2039 0,7435 
10 0,5188 0,9962 0,5112 0,7103 0,4566 1,7542 
3 0,9884 1,0829 1,0319 1,0122 1,7429 1,5941 
1 1,4291 2,1908 1,6584 1,8261 1,813 1,6078 
0,3 1,4949 1,5838 1,4705 1,7289 1,4455 1,7638 
100 0,1471 0,3035 0,205 0,4077 0,1184 1,8755 
33 0,4199 0,6547 0,4123 0,4357 0,1353 1,8722 
10 0,2477 1,2994 0,3948 0,6095 0,2645 1,5843 
3 0,1716 1,4338 1,1202 1,5078 1,5743 1,668 
1 1,2672 2,1441 1,5788 1,6453 2,2171 2,008 
0,3 1,4216 1,2567 1,7504 1,5551 1,7794 1,4253 
 
 
 
 
 
 
 
 
 
 
 
 95 
 
 Raw data from third biological testing   
CONC. COMP 25 COMP 26 COMP 27 COMP 28 COMP 16      DMSO 
100 0,1996 0,2871 0,1992 0,3655 0,1381 1,6357 
33 0,2805 0,6743 0,3699 0,2803 0,1520 1,6485 
10 0,5559 1,6483 0,4998 0,5645 0,1953 2,4906 
3 1,1870 2,8969 1,9694 1,4813 1,2266 1,5936 
1 1,4262 2,1855 1,7735 2,0229 1,4617 2,2620 
0,3 1,4710 1,3065 1,0747 1,1786 1,0990 1,6607 
100 0,2364 0,2937 0,2597 0,2551 0,1291 1,6358 
33 0,2781 0,6135 0,3117 0,2637 0,1651 1,6383 
10 0,4013 1,0357 0,4724 0,3823 0,1830 1,6738 
3 1,1031 1,8624 1,2410 1,1498 0,5297 1,5635 
1 1,1933 1,4519 1,5319 1,3481 0,5928 1,1338 
0,3 0,8682 1,4830 1,1611 1,2544 0,7269 0,6814 
 
 
 
 
 
 
